

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)[Add to Cart](#)[Images](#)

(1 of 1)

United States Patent
Ryan**7,273,718**
September 25, 2007

Isolated genomic polynucleotide fragments from chromosome 10q25.3 that encode human soluble aminopeptidase P

Abstract

The invention is directed to an isolated genomic polynucleotide fragment that encodes human soluble (cytosolic) aminopeptidase P, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human soluble aminopeptidase P and to diagnose, treat, prevent and/or ameliorate a pathological disorder.

Inventors: Ryan; James W. (Augusta, GA)**Assignee: Ryogen LLC** (Suffern, NY)**Appl. No.: 10/457,715****Filed: June 9, 2003**

Related U.S. Patent Documents

<u>Application Number</u>	<u>Filing Date</u>	<u>Patent Number</u>	<u>Issue Date</u>
60386941	Jun., 2002		

Current U.S. Class:

435/252.3; 435/320.1; 435/6; 435/69.1; 977/704

Current International Class: C12N 15/11 (20060101); C12N 15/17 (20060101); C12N 15/79 (20060101); C12Q 1/68 (20060101)

References Cited [\[Referenced By\]](#)

U.S. Patent Documents

6399349	June 2002	Ryan et al.
6812339	November 2004	Venter et al.
2004/0265849	December 2004	Cargill et al.

Other References

Printed alignment of the nucleotide sequences of SEQ ID No. 13,390 of US Patent No. 6,399,349 and SEQ ID No. 2 of this application. cited by examiner .

Sprinkle, T.J., et al., 1998, "Assignemtn of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25", Genomics, vol. 50, pp. 114-116. cited by examiner .

Cottrell, G.S., et al., 2000, "Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single Manganese(II)-dependent enzyme", Biochemistry, vol. 39, pp. 15121-15128. cited by examiner .

Sprinkle, T.J., et al., 2000, "Cloning, chromosomal sublocalization of the human soluble aminopeptidase P Gene (XPNPEP1) to 10q25.3 . . . ", Archives of Biochemistry and Biophysics, vol. 387, No. 1, pp. 51-56. cited by examiner.

Primary Examiner: Bragdon; Kathleen Kerr

Assistant Examiner: Moore; William W.

Attorney, Agent or Firm: Agris; Cheryl H. The Law Offices of Cheryl H. Agris

Parent Case Text

PRIORITY CLAIM

This application claims priority to provisional application Ser. No. 60/386,941, filed Jun. 7, 2002 under 35 U.S.C. 119(e), the contents of which are incorporated herein by reference.

Claims

What is claimed is:

1. An isolated genomic polynucleotide, wherein said polynucleotide can be isolated from human

chromosome 10 and is selected from the group consisting of: (a) a polynucleotide consisting of the nucleic acid sequence set forth in SEQ ID NO:2, (b) a polynucleotide consisting of the sequence of nucleotides from position 12803 to position 55760 of SEQ ID NO:2, and (c) a polynucleotide which is the complement of a polynucleotide of (a) or (b) and encodes a polypeptide having aminoacyl prolyl peptidyl hydrolase activity.

2. A composition comprising the polynucleotide of claim 1 and a carrier.

3. An expression vector comprising a polynucleotide consisting of the sequence of nucleotides from position 12803 to position 55760 of SEQ ID NO:2 or the complement thereof in operable linkage with a heterologous promoter.

4. A recombinant host cell comprising the expression vector of claim 3.

5. A method for obtaining a polypeptide having aminoacyl prolyl peptidyl hydrolase activity comprising (a) culturing the recombinant host cell of claim 4 under conditions that provide for the expression of said polypeptide, and (b) recovering said expressed polypeptide.

6. A method of identifying a nucleotide sequence variant of SEQ ID NO:2 or its complementary sequence comprising (a) isolating genomic DNA from a subject, and (b) determining the presence or absence of a nucleotide sequence variation in said genomic DNA by comparing the nucleotide sequence of SEQ ID NO:2 with the nucleotide sequence of the isolated genomic DNA and establishing if and where a difference occurs between the two nucleotide sequences thereby identifying a nucleotide sequence variant of SEQ ID NO:2.

7. The method according to claim 6, wherein the presence or absence of a nucleotide sequence variation is determined in a 5'-noncoding region, 3'-noncoding region or intron region of SEQ ID NO:2 or its complementary sequence.

8. An isolated polynucleotide consisting of a nucleic acid sequence selected from the group consisting of (a) a sequence of at least 5000 contiguous nucleotides within the region consisting of the sequence of nucleotides from position 1 through position 12802 of SEQ ID NO:2, (b) a sequence of at least 2000 contiguous nucleotides within the region consisting of the sequence of nucleotides from position 55761 through position 58735 of SEQ ID NO:2, (c) a sequence of nucleotides complementary to the nucleotide sequence of (a), and (d) a sequence of nucleotides complementary to the nucleotide sequence of (b).

9. A composition comprising the polynucleotide of claim 8 and a carrier.

10. A kit comprising one or more polynucleotides of claim 8, optionally labeled.

11. The kit according to claim 10, wherein which further comprises the polynucleotide of clause (b) of claim 1 or its complementary sequence, optionally labelled.

12. A solid support comprising one or more polynucleotides of claim 8.

13. The solid support of claim 12 wherein said support is a microarray.
14. The solid support of claim 12, wherein said solid support is a microarray, and wherein the microarray further comprises a polynucleotide of claim 1.
15. A method of detecting the presence or absence of a polynucleotide having the nucleic acid sequence set forth in SEQ ID NO:2 or its complementary sequence in a sample, said method comprising (a) contacting the sample with a polynucleotide of claim 8 in 50% formamide and 5.times.SCC at 65.degree. C., and (b) determining whether the polynucleotide binds to a polynucleotide sequence in the sample, wherein binding of a polynucleotide of the sample to a polynucleotide of claim 6 detects the presence of a polynucleotide comprising SEQ ID NO:2.
16. An isolated polynucleotide consisting of a fragment of the polynucleotide of claim 1, said fragment consisting of an intron region of SEQ ID NO:2 selected from the group consisting of the sequence of nucleotides, between positions 18525 19411, the sequence of nucleotides between positions 19481 20985, the sequence of nucleotides between positions 21046 23146, the sequence of nucleotides between positions 23219 25408, the sequence of nucleotides between positions 25679 28128, the sequence of nucleotides between positions 28873 30372, the sequence of nucleotides between positions 32088 34184, the sequence of nucleotides between positions 34284 36002, the sequence of nucleotides between positions 36550 39674, and the sequence of nucleotides between positions 41031 55646 of SEQ ID NO:2 and nucleic acid sequence regions that are the complements thereof.
17. A composition comprising the polynucleotide of claim 16 and a carrier.
18. A kit comprising one or more polynucleotides of claim 16, optionally labeled.
19. A solid support comprising one or more polynucleotides of claim 16.
20. The solid support of claim 19 wherein said support is a microarray.
21. A method of detecting the presence or absence of a polynucleotide having the nucleic acid sequence set forth in SEQ ID NO:2 or its complementary sequence in a sample, said method comprising (a) contacting the sample with a polynucleotide of claim 15 in 50% formamide and 5.times.SCC at 65.degree. C., and (b) determining whether the polynucleotide binds to a polynucleotide sequence in the sample, wherein binding of a polynucleotide of the sample to a polynucleotide of claim 16 detects the presence of a polynucleotide comprising SEQ ID NO:2.

Description

FIELD OF THE INVENTION

The invention is directed to isolated genomic polynucleotide fragments that encode human soluble (cytosolic) aminopeptidase P, vectors and hosts containing these fragments and fragments hybridizing to

noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human soluble aminopeptidase P and to diagnose, treat, prevent and/or ameliorate a pathological disorder.

BACKGROUND OF THE INVENTION

Chromosome 10 contains genes encoding, for example, the alpha-2A-adrenergic receptor, the beta-1-adrenergic receptor, glyceryl-3-phosphate acyltransferase and G protein-coupled receptor kinase-5. Recently, it has been shown that the soluble (cytosolic) aminopeptidase P gene (XPNPEP1) is disposed at 10q25.3 (Sprinkle et al. Arch. Biochem. Biophys. 378: 51 6, 2000), a gene discussed in further detail below.

Human Soluble Aminopeptidase P

Human soluble aminopeptidase P, an aminoacylprolyl peptidyl hydrolase, catalyzes the removal of the N-terminal amino acid from peptides in which the second residue is proline. It is believed to act physiologically by degrading peptide hormones such as bradykinin and substance P. It may also degrade collagen-related peptides that have N-terminal sequences of the type Xaa-Pro-Hyp-. A functionally-related enzyme is membrane-bound aminopeptidase P, the gene for which (XPNPEP2) is disposed at chromosome Xq25 (Sprinkle et al, Genomics 50: 114 6, 1998). The membrane-bound enzyme is disposed, via a glycosylphosphatidylinositol lipid anchor, as an ectoenzyme on endothelia and epithelia. Soluble aminopeptidase P is disposed intracellularly in virtually all cell types, including astrocytes, lymphocytes, platelets and chromaffin cells.

OBJECTS OF THE INVENTION

Although cDNA encoding the above-disclosed protein, soluble aminopeptidase P, has been isolated (e.g. see accession no. AF195530), its exact location on chromosome 10q25.3 and exon/intron/regulatory organization have not been determined. Furthermore, genomic DNA encoding the polypeptide has not been isolated. Noncoding sequences play a significant role in regulating the expression of polypeptides as well as the processing of RNA encoding these polypeptides.

There is clearly a need for obtaining genomic polynucleotide sequences encoding the soluble aminopeptidase P polypeptide. Therefore, it is an object of the invention to isolate such genomic polynucleotide sequences.

There is also a need to develop means for identifying mutations, duplications, translocations, polysomies and mosaicism as may affect the soluble aminopeptidase P gene.

SUMMARY OF THE INVENTION

The invention is directed to an isolated genomic polynucleotide, said polynucleotide obtainable from human chromosome 10 having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polynucleotide encoding human soluble aminopeptidase P depicted in SEQ ID NO:1; (b) a polynucleotide consisting of SEQ ID NO:2, which encodes human soluble aminopeptidase

P depicted in SEQ ID NO:1; (c) a polynucleotide which is a variant of SEQ ID NO:2; (d) a polynucleotide which is an allelic variant of SEQ ID NO:2; (e) a polynucleotide which encodes a variant of SEQ ID NO:1; (f) a polynucleotide which hybridizes to any one of the polynucleotides specified in (a) (e) and a polynucleotide that is a reverse complement to the polynucleotides specified in (a) to (f) as well as nucleic acid constructs, expression vectors and host cells containing these polynucleotide sequences.

The polynucleotides of the present invention may be used to modulate human soluble aminopeptidase P levels in subjects (e.g., human patients) in need thereof and thus for the manufacture of a gene therapy for the prevention, treatment or amelioration of a medical condition by adding an amount of a composition comprising said polynucleotide effective to prevent, treat or ameliorate said medical condition.

The invention is further directed to obtaining human soluble aminopeptidase P or variant thereof by (a) culturing host cells comprising these sequences under conditions that provide for the expression of said polypeptide and (b) recovering said expressed polypeptide. The polypeptides obtained may be used to produce antibodies by (a) optionally conjugating said polypeptide to a carrier protein; (b) immunizing a host animal with said polypeptide or peptide-carrier protein conjugate of step (b) with an adjuvant and (c) obtaining antibody from said immunized host animal.

The invention is further directed to a nucleic acid molecule including but not limited to a polynucleotide fragment, antisense oligonucleotide or antisense mimetic comprising a sequence of nucleotides which specifically hybridizes to noncoding regions of said polynucleotide sequences of SEQ ID NO:2 (human soluble aminopeptidase P). These sequences may be used to modulate levels of human soluble aminopeptidase P in a subject in need thereof and specifically for the manufacture of a medicament for prevention, treatment or amelioration of a medical condition. As defined herein, a "polynucleotide fragment" may be a nucleic acid molecule including DNA, RNA and analogs thereof including protein nucleic acids and mixtures thereof and may include a probe and primer. Such molecules are generally of a length such that they are statistically unique in the genome of interest. Generally, for a probe or primer to be unique in the human genome, it contains at least 14 to 16 contiguous nucleotides of a sequence complementary to or identical to a target sequence of interest. These polynucleotide fragments can be 20, 30, 50, 100, 150, 500, 600, 1000, 2000 or more nucleic acids long. Probes and primers may also be referred to as oligonucleotides. As defined herein, an "antisense oligonucleotide" is a molecule encoding a sequence complementary to at least a portion of an RNA molecule. The sequence is sufficiently complementary to be able to hybridize with the RNA, preferably under moderate or high stringency conditions to form a stable duplex or triplex.

The invention is further directed to kits comprising these polynucleotides and kits comprising these sequences. In a specific embodiment, the sequence(s) are attached to a substrate. In a specific embodiment, the support is a microarray. The microarray may contain a plurality of sequences hybridizing to non-coding sequences. As defined herein, a "plurality" of sequences is two or more sequences. Alternatively, the microarray comprises non-coding sequences as well as coding sequences.

In a specific embodiment, the noncoding regions are transcription regulatory regions. The transcription regulatory regions may be used to produce a heterologous peptide by expressing in a host cell, said transcription regulatory region operably linked to a polynucleotide encoding the heterologous polypeptide

and recovering the expressed heterologous polypeptide.

The polynucleotides of the present invention may be used to detect a pathological condition or susceptibility to a pathological condition in a subject comprising (a) isolating genomic DNA from said subject; (b) detecting the presence or absence of a variant in said genomic DNA using a probe or primer derived from a polynucleotide hybridizing to non-coding region(s) of said human aminopeptidase P; and (c) diagnosing a pathological condition or susceptibility to a pathological condition based on the presence or absence of said variant.

Probes or primers derived from SEQ ID NO:2 (human soluble aminopeptidase P) may be used to identify variants including but not limited to mutations, duplications, translocations, polysomies and mosaicism on the human soluble aminopeptidase P gene and may be used to identify patients with or having a propensity for conditions in which bradykinin or substance P is produced in excess, e.g., inherited angioedema or acute pancreatitis.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to isolated genomic polynucleotide fragments that encode human soluble aminopeptidase P, which in a specific embodiment is the human soluble aminopeptidase P gene, as well as vectors and hosts containing these fragments and polynucleotide fragments hybridizing to noncoding regions, as well as antisense oligonucleotides to these fragments.

As defined herein, a "gene" is the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region, as well as intervening sequences (introns) between individual coding segments (exons).

As defined herein, "isolated" refers to material removed from its original environment and is thus altered "by the hand of man" from its natural state. An isolated polynucleotide can be part of a vector, a composition of matter or can be contained within a cell as long as the cell is not the original environment of the polynucleotide.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA, which DNA includes genomic DNA and synthetic DNA. The DNA may be double-stranded or single-stranded and if single stranded may be the coding strand or non-coding strand. The human soluble aminopeptidase P gene is 58735 base pairs in length and contains 19 exons (see Table 1 below for location of exons). As will be discussed in further detail below, the gene is situated in genomic clones AL133416 and AL354951.

The polynucleotides of the invention have at least a 95% identity and may have a 96%, 97%, 98% or 99% identity to the polynucleotides depicted in SEQ ID NO:2 as well as the polynucleotides in reverse sense orientation, or the polynucleotide sequences encoding the human soluble aminopeptidase P polypeptide depicted in SEQ ID NO:1.

A polynucleotide having 95% "identity" to a reference nucleotide sequence of the present invention, is identical to the reference sequence except that the polynucleotide sequence may include, on average, up to

five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are:

Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total numbers of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with

the query sequence are manually corrected for. No other manual corrections are made for purposes of the present invention.

A polypeptide that has an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence is identical to the query sequence except that the subject polypeptide sequence may include on average, up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the referenced sequence or in one or more contiguous groups within the reference sequence.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Com. App. Biosci. (1990) 6:237 245). In a sequence alignment, the query and subject sequence are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

The invention also encompasses polynucleotides that hybridize to the polynucleotides depicted in SEQ ID NO: 2. A polynucleotide "hybridizes" to another polynucleotide, when a single-stranded form of the polynucleotide can anneal to the other polynucleotide under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al., supra). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a temperature of 42 C, can be used, e.g.,

5.times.SSC, 0.1% SDS, 0.25% milk, and no formamide; or 40% formamide, 5.times.SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher temperature of 55 C, e.g., 40% formamide, with 5.times. or 6.times.SCC. High stringency hybridization conditions correspond to the highest temperature of 65 C, e.g., 50% formamide, 5.times. or 6.times.SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of $T_{sub.m}$ for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher $T_{sub.m}$) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.

Polynucleotide and Polypeptide Variants

The invention is directed to both polynucleotide and polypeptide variants. A "variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar and in many regions, identical to the polynucleotide or polypeptide of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5, 10, 15, or 20 amino acids are substituted, deleted, or added in any combination are also preferred.

The invention also encompasses allelic variants of said polynucleotides. An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

The amino acid sequences of the variant polypeptides may differ from the amino acid sequences depicted in SEQ ID NO:1 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids

(phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R. L. Hill, 1979, In, *The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, as well as these in reverse.

Noncoding Regions

The invention is further directed to polynucleotide fragments containing or hybridizing to noncoding regions of the human soluble aminopeptidase P gene. These include but are not limited to an intron, a 5'-non-coding region, a 3'-non-coding region and splice junctions (see Table 1), as well as transcription factor binding sites (see Table 2). The polynucleotide fragments may be a short polynucleotide fragment which is between about 20 nucleotides to about 50 nucleotides in length. Such shorter fragments may be useful for diagnostic purposes. Such short polynucleotide fragments are also preferred with respect to polynucleotides containing or hybridizing to polynucleotides containing splice junctions. Alternatively larger fragments, e.g., of about 50, 150, 500, 600, 2000 or about 5000 nucleotides in length may be used.

TABLE-US-00001 TABLE 1 Exon/Intron Regions of the Human Soluble Aminopeptidase P gene (reverse strand coding). Nucleotide no. Exons (stop codon 12803 5) Peptide amino acid no. 19 12806 12931 623 582 18 16233 16331 581 549 17 17572 17649 548 523 16 18351 18524 522 465 15 19412 19480 464 442 14 20986 21045 441 422 13 23147 23218 421 398 12 25409 25489 397 371 11 25622 25678 370 352 10 28129 28179 351 335 9 28783 28872 334 305 8 30373 30582 304 235 7 32007 32087 234 208 6 34185 34283 207 175 5 36003 36146 174 127 4 36457 36549 126 96 3 39675 39779 95 61 2 40965 41030 60 39 1 55647 55760 38 1

TABLE-US-00002 TABLE 2 Transcription Factor Binding Sites of the Human Soluble Aminopeptidase P Gene. Sites No. of Sites AP1_C 12 AP4_Q5 15 AP4_Q6 6 DELTAEF1_019 GATA1_06 4 GATA2_02 4 GATA_C 4 LMO2COM_02 8 LYF1_01 14 MYOD_Q6 12 MZF1_01 34 NFAT_Q6 10 NKX25_01 27 S8_01 12 SOX5_01 39 TATA_C 7 TCF11_01 37 USF_C 18

In a specific embodiment, such noncoding sequences are expression control sequences. These include but are not limited to DNA regulatory sequences, such as promoters, enhancers, repressors, terminators, and the like, that provide for the regulation of expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are also control sequences.

In a more specific embodiment of the invention, the expression control sequences may be operatively linked to a polynucleotide encoding a heterologous polypeptide. Such expression control sequences may be about 50 200 nucleotides in length and specifically about 50, 100, 200, 500, 600, 1000, 2000 or 5000 nucleotides in length. A transcriptional control sequence is "operatively linked" to a polynucleotide encoding a heterologous polypeptide sequence when the expression control sequence controls and regulates the transcription and translation of that polynucleotide sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the

control of the expression control sequence and production of the desired product encoded by the polynucleotide sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted upstream (5') of and in reading frame with the gene.

The invention is further directed to antisense oligonucleotides and mimetics to these polynucleotide sequences. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature polypeptides of the present invention, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription or RNA processing (triple helix (see Lee et al., *Nucl. Acids Res.*, 6:3073 (1979); Cooney et al, *Science*, 241:456 (1988); and Dervan et al., *Science*, 251: 1360 (1991)), thereby preventing transcription and the production of said polypeptides.

Expression of Polypeptides

Isolated Polynucleotide Sequences

The human chromosome genomic clones of accession number AL133416 and AL354951 have been discovered to contain the human soluble aminopeptidase P gene by Genscan analysis (Burge et al., 1997, *J. Mol. Biol.* 268:78 94), BLAST2 and TBLASTN analysis (Altschul et al., 1997, *Nucl. Acids Res.* 25:3389 3402), in which the sequences of AL133416 and AL354951 were compared to the human soluble aminopeptidase P cDNA sequence, accession number AF195530

The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) or long range PCR may be used. In a specific embodiment, 5'- or 3'-non-coding portions of the gene may be identified by methods including but are not limited to, filter probing, clone enrichment using specific probes and protocols similar or identical to 5'- and 3'-"RACE" protocols which are well known in the art. For instance, a method similar to 5'-RACE is available for generating the missing 5'-end of a desired full-length transcript. (Fromont-Racine et al., 1993, *Nucl. Acids Res.* 21:1683 1684).

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired human soluble aminopeptidase P gene may be accomplished in a number of ways. For example, if an amount of a portion of a human soluble aminopeptidase P gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, *Science* 196:180; Grunstein and Hogness, 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). The present invention provides such nucleic acid probes, which can be conveniently prepared from the specific sequences disclosed herein, e.g., a

hybridizable probe having a nucleotide sequence corresponding to at least a 10, and preferably a 15, nucleotide fragment of the sequences depicted in SEQ ID NO:2. Preferably, a fragment is selected that is highly unique to the polypeptides of the invention. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In one embodiment, low stringency hybridization conditions are used to identify a homologous human soluble aminopeptidase P polynucleotide. However, in a preferred aspect, and as demonstrated experimentally herein, a nucleic acid encoding a polypeptide of the invention will hybridize to a nucleic acid derived from the polynucleotide sequence depicted in SEQ ID NO:2 or a hybridizable fragment thereof, under moderately stringent conditions; more preferably, it will hybridize under high stringency conditions.

Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, or antigenic properties as known for the human soluble aminopeptidase P polypeptide.

A gene encoding human soluble aminopeptidase P polypeptide can also be identified by mRNA selection, i.e., by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Immunoprecipitation analysis or functional assays of the *in vitro* translation products of the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments, that contain the desired sequences.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a polynucleotide sequence containing the exon/intron segments of the human soluble aminopeptidase P gene (nucleotides 58735 of SEQ ID NO:2) operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

The invention is further directed to a nucleic acid construct comprising expression control sequences derived from SEQ ID NO: 2 and a heterologous polynucleotide sequence.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding sequence" is defined herein as a portion of a nucleic acid sequence which directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by a ribosome binding site (prokaryotes) or by the ATG start codon (eukaryotes)

located just upstream of the open reading frame at the 5'-end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3'-end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

The isolated polynucleotide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing recombinant DNA methods are well known in the art.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences which regulate the expression of the polynucleotide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli* lac operon, the *Streptomyces coelicolor* agarase gene (*dagA*), the *Bacillus subtilis* levansucrase gene (*sacB*), the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), the *Bacillus licheniformis* penicillinase gene (*penP*), the *Bacillus subtilis* *xylA* and *xylB* genes, and the prokaryotic beta-lactamase gene (Villa-Komaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75: 3727 3731), as well as the *tac* promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80: 21 25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242: 74 94; and in Sambrook et al., 1989, supra.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium oxysporum* trypsin-like protease (WO 96/00787), NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* galactokinase gene (*GAL1*), the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (*ADH2/GAP*), and the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8: 423 488.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by

a host cell to terminate transcription. The terminator sequence is operably linked to the 3'-terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention. Preferred terminators for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes encoding *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), or *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.

The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5'-terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

Preferred leaders for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene, the *Saccharomyces cerevisiae* alpha-factor, and the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3'-terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, and *Aspergillus niger* alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15: 5983 5990.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the encoded polypeptide into the cell's secretory pathway. The 5'-end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5'-end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural

signal peptide coding region in order to obtain enhanced secretion of the polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from *Bacillus* NCIB 11837, the *Bacillus stearothermophilus* alpha-amylase gene, the *Bacillus licheniformis* subtilisin gene, the *Bacillus licheniformis* beta-lactamase gene, the *Bacillus stearothermophilus* neutral proteases genes (nprT, nprS, nprM), or the *Bacillus subtilis* prsA gene. Further signal peptides are described by Simonen and Palva, 1993, *Microbiological Reviews* 57: 109-137.

An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained from the *Aspergillus oryzae* TAKA amylase gene, *Aspergillus niger* neutral amylase gene, *Aspergillus niger* glucoamylase gene, *Rhizomucor miehei* aspartic proteinase gene, *Humicola lanuginosa* cellulase gene, or *Humicola lanuginosa* lipase gene.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, *supra*.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (aprE), the *Bacillus subtilis* neutral protease gene (nprT), the *Saccharomyces cerevisiae* alpha-factor gene, the *Rhizomucor miehei* aspartic proteinase gene, or the *Myceliophthora thermophila* laccase gene (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and the *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the polynucleotide of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.

The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Suitable markers for yeast host cells are *ADE2*, *HIS3*, *LEU2*, *LYS2*, *MET3*, *TRP1*, and *URA3*. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5O-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), as well as equivalents from other species. Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

For integration into the host cell genome, the vector may rely on the polynucleotide sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional polynucleotide sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM.sctn.1 permitting replication in *Bacillus*. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75: 1433).

More than one copy of a polynucleotide sequence of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the polynucleotide sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, e.g., *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas sp.* In a preferred embodiment, the bacterial host cell is a *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus* or *Bacillus subtilis* cell. In another preferred embodiment, the *Bacillus* cell is an alkalophilic *Bacillus*.

The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Molecular General Genetics* 168: 111 115), using competent cells (see, e.g., Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823 829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209 221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742 751), or conjugation (see, e.g., Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771 5278).

The host cell may be a eukaryote, such as a mammalian cell (e.g., human cell), an insect cell, a plant cell or a fungal cell. Mammalian host cells that could be used include but are not limited to human HeLa, 293, H9 and Jurkat cells, mouse NIH3t3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese Hamster ovary (CHO) cells. These cells may be transfected with a vector containing a transcriptional regulatory sequence, a protein coding sequence and transcriptional termination sequences. Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The host cell may be a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra). The fungal host cell may also be a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F. A., Passmore, S. M., and Davenport, R. R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980). The fungal host cell may also be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the

protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier et al., 1989, Gene 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J. N. and Simon, M. I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153: 163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75: 1920.

Methods of Production

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. In a specific embodiment, an enzyme assay may be used to determine the activity of the polypeptide. For example, human soluble aminopeptidase P can be assayed by its ability to release the N-terminal arginine residue from bradykinin or the synthetic substrate Arg-Pro-Pro-benzylamide.

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Antibodies

According to the invention, the human soluble aminopeptidase P polypeptide produced according to the method of the present invention may be used as an immunogen to generate any of these antibodies. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.

Various procedures known in the art may be used for the production of antibodies. For the production of antibody, various host animals can be immunized by injection with the polypeptide thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the polypeptide or fragment thereof can optionally be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the human soluble aminopeptidase P polypeptide, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495 497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77 96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026 2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77 96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *J. Bacteriol.* 159 870; Neuberger et al., 1984, *Nature* 312:604 608; Takeda et al., 1985, *Nature* 314:452 454) by splicing the genes from a mouse antibody molecule specific for the human soluble aminopeptidase P polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, *Science* 246:1275 1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for the human soluble aminopeptidase P polypeptide.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab').sub.2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab').sub.2, fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of a particular polypeptide, one may assay generated hybridomas for a product which binds to a particular polypeptide fragment containing such epitope. For selection of an antibody specific to a particular polypeptide from a particular species of animal, one can select on the basis of positive binding with the polypeptide expressed by or isolated from cells of that species of animal.

Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., "Hybridoma Techniques" (1980); Hammerling et al., "Monoclonal Antibodies And T-cell Hybridomas" (1981); Kennett et al., "Monoclonal Antibodies" (1980); see also U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890.

Substrate

In a specific embodiment, the polynucleotides of the present invention, particularly, the polynucleotide fragments or antisense nucleic acids hybridizing to non-coding regions of SEQ ID NO:2 may be attached to a substrate. A substrate may be solid or porous, planar or non-planar, unitary or distributed. The polynucleotide may be attached covalently or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combinations thereof.

In a more specific embodiment, the substrate is a microarray. "Microarray" as defined herein is a substrate-bound collection of a plurality nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The microarray may comprise a plurality of polynucleotides hybridizing to a non coding region of SEQ ID NO:2. Alternatively the microarray may comprise a polynucleotide(s) hybridizing to said non-coding region and/or coding regions of SEQ ID NO:2.

Uses of Polynucleotides

Diagnostics

Polynucleotide fragments containing noncoding regions of SEQ ID NO:2 may be used as probes for detecting variants from genomic nucleotide samples from a patient. The variants may be allelic variants or substitution, insertion or deletion nucleotide variants. Genomic DNA may be isolated from the patient. A

mutation(s) may be detected by Southern blot analysis, specifically by hybridizing restriction digested genomic DNA to various probes between 10 500 nucleotides in length, preferably between 20 200 nucleotides in length, more preferably between 20 100 nucleotides in length and most preferably between 20 50 nucleotides in length and subjecting to agarose electrophoresis. Alternatively, these polynucleotides may be used as PCR primers between about 10 100 nucleotides in length and be used to amplify the genomic DNA isolated from the patients. Methods for performing primer-directed amplification (routine or long range PCR) are well known in the art (see, for example, PCR Basics: From Background to Bench, Springer Verlag (2000); Gelfand et al., (eds.), PCR Strategies, Academic Press (1998). Single base extension (see, for example, U.S. Pat. No. 6,004,744) may be used to detect SNPs. Additionally, primers may be obtained by routine or long range PCR that yield products containing contiguous intron(s)/exon sequence(s) and products containing more than one exon with intervening intron. The sequence of the amplified genomic DNA from the patient may be determined using methods known in the art. Such probes may be between 20 5000 nucleotides in length and may preferably be between 20 50 nucleotides in length.

Thus the invention is thus directed to kits comprising these polynucleotide probes. In a specific embodiment, these probes are labeled with a detectable substance.

In one embodiment, the probes are in solution. In another embodiment, the probes are attached to a substrate. In a specific embodiment, the probes are contained within a microarray and are separately detectable.

Antisense Oligonucleotides and Mimetics

The antisense oligonucleotides or mimetics of the present invention may be used to decrease levels of a polypeptide. For example, human soluble aminopeptidase P has been found to be associated with the inactivation of bradykinin, an antimitogenic agent. Therefore, the human soluble aminopeptidase P antisense oligonucleotides of the present invention could be used to inhibit cell growth and in particular, to treat vascular stenosis or restenosis.

The antisense oligonucleotides of the present invention may be formulated into pharmaceutical compositions. These compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions and formulations for oral administration include powders or granules, suspensions or

solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention, the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅₀ as found to be effective in in vitro and in vivo animal models.

In general, dosage is from 0.01 ug to 10 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily

estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 10 g per kg of body weight, once or more daily, to once every 20 years.

Gene Therapy

As noted above, human soluble aminopeptidase P inactivates bradykinin and substance P. Therefore, the human soluble aminopeptidase P gene may be used to modulate or prevent conditions in which bradykinin or substance P is produced in excess; notably in acquired or inherited angioedema or acute pancreatitis.

As described herein, the polynucleotide of the present invention may be introduced into a patient's cells for therapeutic uses. As will be discussed in further detail below, cells can be transfected using any appropriate means, including viral vectors, as shown by the example, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA. See, for example, Wolff, Jon A, et al., "Direct gene transfer into mouse muscle in vivo," *Science*, 247, 1465 1468, 1990; and Wolff, Jon A, "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," *Nature*, 352, 815 818, 1991. As used herein, vectors are agents that transport the gene into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. As will be discussed in further detail below, promoters can be general promoters, yielding expression in a variety of mammalian cells, or cell specific, or even nuclear versus cytoplasmic specific. These are known to those skilled in the art and can be constructed using standard molecular biology protocols. Vectors have been divided into two classes:

- a) Biological agents derived from viral, bacterial or other sources.
- b) Chemical physical methods that increase the potential for gene uptake, directly introduce the gene into the nucleus or target the gene to a cell receptor.

Biological Vectors

Viral vectors have higher transfection (ability to introduce genes) abilities than do most chemical or physical methods to introduce genes into cells. Vectors that may be used in the present invention include viruses, such as adenoviruses, adeno associated virus (AAV), vaccinia, herpesviruses, baculoviruses and retroviruses, bacteriophages, cosmids, plasmids, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression. Polynucleotides are inserted into vector genomes using methods well known in the art.

Retroviral vectors are the vectors most commonly used in clinical trials, since they carry a larger genetic payload than other viral vectors. However, they are not useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation. Pox viral vectors are large and have several sites for inserting genes, they are thermostable

and can be stored at room temperature.

Examples of promoters are SP6, T4, T7, SV40 early promoter, cytomegalovirus (CMV) promoter, mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, phosphoglycerate kinase (PGK) promoter, and the like. Alternatively, the promoter may be an endogenous adenovirus promoter, for example the E1 a promoter or the Ad2 major late promoter (MLP). Similarly, those of ordinary skill in the art can construct adenoviral vectors utilizing endogenous or heterologous poly A addition signals. Plasmids are not integrated into the genome and the vast majority of them are present only from a few weeks to several months, so they are typically very safe. However, they have lower expression levels than retroviruses and since cells have the ability to identify and eventually shut down foreign gene expression, the continuous release of DNA from the polymer to the target cells substantially increases the duration of functional expression while maintaining the benefit of the safety associated with non-viral transfections.

Chemical/Physical Vectors

Other methods to directly introduce genes into cells or exploit receptors on the surface of cells include the use of liposomes and lipids, ligands for specific cell surface receptors, cell receptors, and calcium phosphate and other chemical mediators, microinjections directly to single cells, electroporation and homologous recombination. Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN** and LIPOFECTACE**, which are formed of cationic lipids such as N-[1-(2,3 dioleoyloxy)-propyl]-n,n,n-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Numerous methods are also published for making liposomes, known to those skilled in the art.

For example, Nucleic acid-Lipid Complexes--Lipid carriers can be associated with naked nucleic acids (e.g., plasmid DNA) to facilitate passage through cellular membranes. Cationic, anionic, or neutral lipids can be used for this purpose. However, cationic lipids are preferred because they have been shown to associate better with DNA which, generally, has a negative charge. Cationic lipids have also been shown to mediate intracellular delivery of plasmid DNA (Felgner and Ringold, *Nature* 337:387 (1989)). Intravenous injection of cationic lipid-plasmid complexes into mice has been shown to result in expression of the DNA in lung (Brigham et al., *Am. J. Med. Sci.* 298:278 (1989)). See also, Osaka et al., *J. Pharm. Sci.* 85(6):612 618 (1996); San et al., *Human Gene Therapy* 4:781 788 (1993); Senior et al., *Biochimica et Biophysica Acta* 1070:173 179 (1991); Kabanov and Kabanov, *Bioconjugate Chem.* 6:7 20 (1995); Remy et al., *Bioconjugate Chem.* 5:647 654 (1994); Behr, J-P., *Bioconjugate Chem* 5:382 389 (1994); Behr et al., *Proc. Natl. Acad. Sci., USA* 86:6982 6986 (1989); and Wyman et al., *Biochem.* 36:3008 3017 (1997).

Cationic lipids are known to those of ordinary skill in the art. Representative cationic lipids include those disclosed, for example, in U.S. Pat. No. 5,283,185; and e.g., U.S. Pat. No. 5,767,099. In a preferred embodiment, the cationic lipid is N.sup.4-spermine cholesteryl carbamate (GL-67) disclosed in U.S. Pat. No. 5,767,099. Additional preferred lipids include N4_spermidine cholesteryl carbamate (GL-53) and 1-(N4-spermind)-2,3-dilaurylglycerol carbamate (GL-89).

The vectors of the invention may be targeted to specific cells by linking a targeting molecule to the vector. A targeting molecule is any agent that is specific for a cell or tissue type of interest, including for example, a ligand, antibody, sugar, receptor, or other binding molecule.

Invention vectors may be delivered to the target cells in a suitable composition, either alone, or complexed, as provided above, comprising the vector and a suitably acceptable carrier. The vector may be delivered to target cells by methods known in the art, for example, intravenous, intramuscular, intranasal, subcutaneous, intubation, lavage, and the like. The vectors may be delivered via in vivo or ex vivo applications. In vivo applications involve the direct administration of an adenoviral vector of the invention formulated into a composition to the cells of an individual. Ex vivo applications involve the transfer of the adenoviral vector directly to harvested autologous cells which are maintained in vitro, followed by readministration of the transduced cells to a recipient.

In a specific embodiment, the vector is transfected into antigen-presenting cells. Suitable sources of antigen-presenting cells (APCs) include, but are not limited to, whole cells such as dendritic cells or macrophages; purified MHC class I molecule complexed to beta2-microglobulin and foster antigen-presenting cells. In a specific embodiment, the vectors of the present invention may be introduced into T cells or B cells using methods known in the art (see, for example, Tsokos and Nepom, 2000, J. Clin. Invest. 106:181-183).

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosure of which are incorporated by reference in their entireties.

>

2Homo sapiens o Pro Lys Val Thr Ser Glu Leu Leu Arg Gln Leu Arg Gln Alarg Asn Ser Glu Tyr Val Thr
 Glu Pro Ile Gln Ala Tyr Ile Ile 2Pro Ser Gly Asp Ala His Gln Ser Glu Tyr Ile Ala Pro Cys Asp Cys 35 4
 Arg Ala Phe Val Ser Gly Phe Asp Gly Ser Ala Gly Thr Ala Ile 5Ile Thr Glu Glu His Ala Ala Met Trp Thr
 Asp Gly Arg Tyr Phe Leu65 7Gln Ala Ala Lys Gln Met Asp Ser Asn Trp Thr Leu Met Lys Met Gly 85 9
 Lys Asp Thr Pro Thr Gln Glu Asp Trp Leu Val Ser Val Leu Pro Gly Ser Arg Val Gly Val Asp Pro Leu Ile
 Ile Pro Thr Asp Tyr Lys Lys Met Ala Lys Val Leu Arg Ser Ala Gly His His Leu Ile Val Lys Glu Asn Leu
 Val Asp Lys Ile Trp Thr Asp Arg Pro Glu Arg Pro Cys Lys Pro Leu Leu Thr Leu Gly Leu Asp Tyr Thr
 Gly Ile Trp Lys Asp Lys Val Ala Asp Leu Arg Leu Lys Met Ala Glu Arg Val Met Trp Phe Val Val Thr
 Ala Leu Asp Glu Ile Ala Trp Leu 2sn Leu Arg Gly Ser Asp Val Glu His Asn Pro Val Phe Phe Ser 222a
 Ile Ile Gly Leu Glu Thr Ile Met Leu Phe Ile Asp Gly Asp225 234e Asp Ala Pro Ser Val Lys Glu His Leu
 Leu Leu Asp Leu Gly 245 25u Glu Ala Glu Tyr Arg Ile Gln Val His Pro Tyr Lys Ser Ile Leu 267u Leu
 Lys Ala Leu Cys Ala Asp Leu Ser Pro Arg Glu Lys Val 275 28p Val Ser Asp Lys Ala Ser Tyr Ala Val

Ser Glu Thr Ile Pro Lys 29is Arg Cys Cys Met Pro Tyr Thr Pro Ile Cys Ile Ala Lys Ala33al Lys Asn Ser
 Ala Glu Ser Glu Gly Met Arg Pro Ala His Ile Lys 325 33p Ala Val Ala Leu Cys Glu Leu Phe Asn Trp
 Leu Glu Lys Glu Val 345s Gly Gly Val Thr Glu Ile Ser Ala Ala Asp Lys Ala Glu Glu 355 36e Arg Arg
 Gln Gln Ala Asp Phe Val Asp Leu Ser Phe Pro Thr Ile 378r Thr Gly Pro Asn Gly Ala Ile Ile His Tyr Ala
 Pro Val Pro385 39hr Asn Arg Thr Leu Ser Leu Asp Glu Val Tyr Leu Ile Asp Ser 44la Gln Tyr Lys Asp
 Gly Thr Thr Asp Val Thr Arg Thr Met His 423y Thr Pro Thr Ala Tyr Glu Lys Glu Cys Phe Thr Tyr Val
 Leu 435 44s Gly His Ile Ala Val Ser Ala Ala Val Phe Pro Thr Gly Thr Lys 456s Leu Leu Asp Ser Phe
 Ala Arg Ser Ala Leu Trp Asp Ser Gly465 478p Tyr Leu His Gly Thr Gly His Gly Val Gly Ser Phe Leu
 Asn 485 49l His Glu Gly Pro Cys Gly Ile Ser Tyr Lys Thr Phe Ser Asp Glu 55eu Glu Ala Gly Met Ile Val
 Thr Asp Glu Pro Gly Tyr Tyr Glu 5525Asp Gly Ala Phe Gly Ile Arg Ile Glu Asn Val Val Leu Val Val
 Pro 534s Thr Lys Tyr Asn Phe Asn Asn Arg Gly Ser Leu Thr Phe Glu545 556u Thr Leu Val Pro Ile Gln
 Thr Lys Met Ile Asp Val Asp Ser 565 57u Thr Asp Lys Glu Cys Asp Trp Leu Asn Asn Tyr His Leu Thr
 Cys 589p Val Ile Gly Lys Glu Leu Gln Lys Gln Gly Arg Gln Glu Ala 595 6eu Glu Trp Leu Ile Arg Glu
 Thr Gln Pro Ile Ser Lys Gln His 662DNAHomo sapiens 2cagagctggc actcagccca tctttattaa atgaactctc
 cctacattcc tgcctacagt 6ctgg gtacaatggc ctctgagagg aactgagtg gcagccacat gagegcctcc cagtag gaaacctga
 gaggtctc cccgtgtcat ccttctctat aataatccat ttctc agctggctgg ccgtctccac tctctccaca gatccacact gccatctget
 24aggc acaggagcat ctaacgccg ctgtgccccg cttgcagggc gtcagcaat 3atgcc tgatgccag agtaatgcc tectaacct
 tggcatgga cagtgcagc 36aact tcaggctctg ttcttgtga ctccaagc atctcctgt actatcctc 42ttca caaattgtc
 tctagttcag aaactgtct tctccacca tcccactgg 48tgca gactccttg acctgggtt agagaaaaga gagcacagaa
 gagagccaga 54ccac tgcagctc agcctctc taaggcactt cactacagat catgatgcc 6ggctt ggtagattt tctatagtga
 gatctgtgat ttgtttgtt cacatttcaa 66agaa atgaggatgc atcttagagt catgaggtct cgtgtgaaaa ctttgacacc 72agag
 atcaagaagc acgagcatta acgtgtctca cttaaatag gtgaagtgca 78gtga attatatctc aataaggta cacttagttt tgttaaagc
 tgtctcaggt 84gggg aacatggatg tatacaaaa gtaacattc aaggatacac tctacaggag 9tcttt cctcctcat agcctaata
 ggagacatcg ccgtaacct cacattacag 96aaat gggggctcag agaggctgtg ctcttgccca gggactcaca gctggtacac gccatc
 gcttagaac ccatgttcta aacctata tactcttctt tccatgtta ctataaa ggaaaaataa aagaaaaatt tctgtttaa gacaacaac
 tttctttt taaaaa aaaaaaagtt atggtaggaa gtatccaaga tctctccaa taggtgaatg aaacaaa cttgtgtat ctgtaacaag
 aacattatc catgataaaa agaaataagc caagcca tgaaggaca tggatgaacc tgaatacat attgctaagt gacagaagcc atgaaa
 attctacatg ctgtttgatt cctattatat ggtatctgga aaaagcaaaa tagagac agtaaaaaa aaaaaaaaa aaaaaaatca ctggtgcca
 ggacctacg aatagg aggtgaaat cagggaagcc caggggatat ttttccagg tggtaaacct ctgtatg attgtgtaat tgtggataca
 tgacactatg cattatcaa aacatactga ttacagc acacagagtg aaccataatg tatgcaaatt gaaaaaaaa aaccatttag gtcaaag
 gaatcccagg atggaatgca gtatgtgata aatgatcta actatattaa gtatgaa actgtaatac ctactgaaa gaaggggagg
 ggggtgagaag gaaggtgctg taagcaa ctttggaat aatgagtgg agtctgtaa accgaagcaa aaataattgc taaacac taaactcggc
 cgggtgtggt ggctcatgcc tgaatccca gcatttggg ccgaggc aggcggatca cgaggtcagc agaacgagac catctggct
 aacagggtga cccatc ctactaaaa atacaaaaa ttagccagc gtggtggctg gcacctgtag cagctac tggggaggct
 gaggcaggag aacggcgtga accggggagg cggagcttg 2agcgga gatggcgcca ctgactcca gctgggcca gagagcaaga
 ttccgtctaa 2aaaaa aaaccacct actcaagtg ataaagtgt tcccacagt atacaggtta 2cttaa cactgtaca catgtacat
 agaattaagc aattaagtga aatataagt 222atgg cggatggtgg gagccaagtt ctactgatg aagtaggaag tcacagagaa
 228ggag atgatcatga attagagtg gagacatcag tgtgaactca tgttagtt 234gaaa cagatggtta catatagaaa cactgaaaga
 tagttgtgtg tgtatatata 24acata tacatagca tactctttg tcttgctct cagctgagac ggcttagcag 246caag ccagtaagag
 aacctatcta gtgctcagat cttggtttta ttatttatt 252ttta tgagatggag ttactctt gcatccagg ctgaagtgca gtggcatgat
 258tcac tgcaacctcc acttctggg tcaagtgat tctccagct cagctccc 264tggg attacaggtg cccaccacca ggcccagcta
 attttgtat ttttagtaga 27ggtgt aattttgta ttttagtac agacagggtt tgccatgtt ggccaggctg 276aact cctgaccca
 ggtgatctgc ccgctcggc ctctaaact gctgggatta 282tgag ccacatgcc cagctggat cttggtttta aatacttct cccgtaaaa

288agag cttcttaaag aatgattga ttctagaatt ggagcaggaa atacacaaga 294tgga gcaatttga gtgccagaaa gtaaagaagt
 gttacaaca cacacacaca 3cacaca cacacacaca cacacgatgg gatatacaa aggaacacag gagacagctg 3agccct
 cagtggccaa agctggaaca atttaaagaa agcagtattg attataatcc 3tataaa ataaatatct gcaagcctat acaaatatga aaaaataaaa
 gaatgtggaa 3agacaa atctgtgcag aagcattcta aataattac atatattctg tgcctcaag 324gaac ataactcca ctcttaagt
 atgggctaca cgtagtact ttccaagaat 33ataag caggggggtg aaagagtcac ttcctatgg agaaatatga caaacactgc 336caga
 tgatcaaggt taacctcacc agtcaaaagc catgttgata gtatgtacc 342tgat gtgacaaaaa tggcacttta ctccatcga ctccgccta
 taaaactaaa 348gtct aatcatgaga aaaatattta aatcccaat ataaggatat tccacaaaat 354ccag tattctcaa aactgtccag
 gtcacaaaa atgaagaaaa tetaagaaac 36cagcc taagaagaca ggacaactaa atataatgag ggactccgga tgggattctg
 366aaaa aggacattag ctaaaaacta gggaaactg aataaagtc agcctttagt 372tact gcgataacat tggttcgta attgtgacag
 atgtactata ctaagatctg 378agtg aaaactaggt gtggagcata aagaactct ctgtactttc ttcgcagtaa 384aact gttctaaata
 ataaagttg ttttaaaaa taatgatata ggaaattgg 39attg ggaaggaaga aataaggac aataaataga gaattcaaaa cagaattgca
 396cttc ttgttaaaaa atataggtgc cctgtcacga taacaacta acatttactg 4ctgatt acatgcctga cagcatgcta agtgattgt
 gcatattatt tcttttaate 4caaata tctgtcaga atataccacc accctcattt tgtaaaggat gaaactggag 4gagaag atacataatt
 taccaacca aggtcaccag ctaggaagta atgggactga 42attct gctccatca tccattctgt tgtaaactg tttggaatgt ctcatcaat
 426atgt atccatcaat aatattttat tgagtactc ttatgtgcct ggtcctgagc 432tggg gctgggcccc aaggaactac aagtctagt
 ggagagacat gggaaaggtt 438cata aagagaaagt caattacagt ttgtgaagaa aatgaatgcc agcaaaactt 444agga cttgtagctg
 gaataattgg gaaacactc atgaagaagc tatgtgggaa 45ctaga ttctaaagat gggaaggaat tcaaagtga aggacaggag
 gaagccctcc 456aaag gctggagcca atgactgtac ctatctgcct gcagaatagg tgtaaggaa 462caat ccactggtg
 caaacagccc tggcctgaga gccaggagac cagaaattga 468gttg gtcttagcct tcaatctgga cctcatatgg ttcactctt tttgttatt
 474gttg ttgtttgctg agatggagtc ttgctctacc acccaggtg gagtacagt 48atctg ggctcactgc aacctccacc tccaggttc
 aagcaattct cctgcctcag 486gagt agctgggatt acaggttgt gccaccatgc ccagctgatt tttgtaattt 492gtag agactgggtt
 tgcctatgtt ggccagtcta gtttcaaact cctgacctg 498gcct acctcagcct cccaaagtgc tgggattaca atcatgagcc
 accataccc 5ttcaa cactctttaa aaaaaaaaaaag aaaaaaaaaa ggatgtttag aatccacct 5attaga atacagagca ttctggactg
 agaaagagat aagaacatta gctaggtgca 5tgtaat cccagctact tgggaggctg aagaggaagg attgcctgag cccaggagt
 522taca gtgagctatg attgtgccac tgcactccaa cctggacaac agagtgagac 528tgta aataagtaag aagagatcc ccaaccaaat
 gacctagctt gctttttgca 534actt tcagagtgtg cagcggggaa cgettaagcc tcaggtgtct gtgatgctgc 54cgcca accttccct
 ggctccagg ctgccaggaa ggggatcctg gctgggtacc 546taca gagcttgcag tgcagtaaga agccacagct tctgcccag
 aaccaatttt 552caca tgtgtttgt tagacctaca tgagattttg ttttagttg taaaatgta 558ttgt aatgtttta aactaggt
 atgccacat acacagttc agctcctctt 564cctg ttcaggcca gatgtgatgg ctcacgccta taatgccagc acttagggag 57ggcgg
 taggatacta ccttgagccc aggagttaga cacctgcctg ggcagcatag 576catg ttctccacaa aagtaaaaa agacataaaa
 atagtaaaat cacatctca 582ccct gtgagctctc tttatccaa ggcagacagg ctggagatgg gacttctgc 588taca tagagtactg
 ctctccacc catcatagge taactctacc agctctaact 594cttg cccactggc cactgttggc actgttctt tttaaattt ggggtttgtt
 6attgta cttaagttc ttgtatgcat gtgcagaaca tgcaggtttg ttacataagt 6atgtgc catggtggtt tctgcactc atcaacctat
 catccaggtc ttgagccccg 6cattag ggattgtcc ttatggttc cctcccctg cccccacc cccgacagge 6gtgtgt gatgtcccc
 tccctgtgc catgtttct cattgttcaa ctctacttg 624agaa cagagatgt ttgtttct gttctgtgt tagtttctg agaatgatg
 63agctt catcatgct cctgcaaagg acatgaactc attctttta atggctgcat 636ccat ggtgtatag tgcacattt tctttacca
 ctctatcatt gatcggcatt 642ggtt ccaagtctt gctattgtaa atagtccac aataaacata cgtgtgcatg 648tata gaatgattg
 taatccttg ggtatatacc cagtaattggg attgctgggt 654ttgt tattaactt aacacagatg caaacacca tgtaaagca acatggggct
 66aatta cataatgagc acctgttca ctacaactaa tgcatttta ttttctctg 666actg ttgctttgaa aattctgat ggcaatataa tttttttc
 accataagt 672ctt ttgtctgatt aaccaggaaa tttttttg gtacagtaat tctaccataa 678cctg ttgctattc taggtttatt
 tattgattt tacggcatgc ctctcaaag 684ttcg aactttttt tctcagga gtgtttctt atagttttt atattgttc 69cctt agctttctc
 tttgtgaaa cctattatgt aatgttgaa tgtgttgc 696ctat attctttca cttaataat tttattcat tttgtttca attctctt 7catct
 ctgtttatct taagacatta tctgtggtgt ttattcattc ctgttctct 7cttag tcttcaat tcaattgat tttttctca tcttctctc agttctca

7attect cagttctct aattctctgt tgtatattgt tttgcatac actgtttta 72gtaa tgtgcttga acattacaga tttcatctg tttatgggca
tgtctctgtg 726ttca ttgtaggcac gtcattctgc acctatttt cttttctaa ttacatagc 732cctc aaccttttt tctgtttctt atttttatgt
gaaatttttc tgaactctg 738ttta gaatagtttt tttcttattt agggctctag agctcccttt tctgttgatt 744agta ttcaaaaata tagcacttac
ttttggagat ctctggctc tgttccctc 75gaacc ttctttctcc ttgctctcg ctgtacctgt cctgctctc tttggctct 756cage
gtggggcttg gtcgtgggag ttctggggac gctgactgct ccagcccctg 762ttac caaaaacctc tcatactcac cactggagg
tgcaaacctgc tccagtggt 768tgtt ctgagattgg ctccgtgaga ttctgagctc ctgatggcta ttgtggggtt 774tcag gtccatcaga
taccatca ctctctcag ctctctctg cacagatgct 78tacgc tggttagtct tcactgctc ttattaagggt tttgtggaga tgcctgacac
786attt ggtgcaaagc tcatectga attttagttt tctaccca gttatccgt 792atga agttatttgg agagattcaa acactatgac
acaactgctg ccacttgcc 798tgca tctgtttct taatccatga ttctatgaat ttcttaactg ctgcaccagc 80gtagg aactagcaag
cacagtatcc ttctccct ctctcagccc tccagttcc 80ctgtc tctgtctaga ggccaacggt gcttgaaaga tccccaaag cactctact
8ttcata tcattactgg tataaacccc cagttgctgg gaaacagag ggcaaacct 822tggc ttgttagtcc aacctgggt ctttcacaa
ttgccaccc ctaaccggga 828ctga tgaggaacaa ctgatggta ctgtcaggca gccagatgcc aggcacagcc 834ctaa
agaagtggg agagctgggg tgggggggc agccccctca ctggcaggag 84gatgg actctttcca gaaggcgaac aagcgtcca
caagtcagtc cctggagtgt 846cagg ggccccacat ctgtccctt cttgaatcc tctacctta tacataaac 852aggg aatacagtga
gcaagacaaa gaaacagat cagcttctt cttaaattc 858atgc ccatttctt acccaacatt tttttatca tttattaaa agtgaggag
864tttt tttttttta tctacattt tctctctca tctctctct gagctctggc 87agagt ttattctgg tctcaatcc ttatggggcc atcttgccta
gtttatgtct 876ctta atgccaagac aaagcaggtc caggcaggaa gctccaagca ccagcacct 882tttg ctctcgggc tacagccaat
taaatcaaac tttgctctga ggctgcctg 888aaca ggttaacag cctgatgaac agacagtgga gttgccgca cacttgagt 894attt
caactccaaa tcaactgca ttcatgcctc ccatttctc agcaagagaa 90tggga tctcagagaa gacaacagcc tgagtctaa
gggaaatctt ctaacttcca 90atgac agatgagaaa catgcttaat acattctatc atttggggag aaatttctt 90agcca atgtatggt
acatattaga aatatgaca agcatggaca aaaggcattc 90attgat ctttgatgga tcaaaatag tctattatt gggaggcact gcttctatgc
924gacc tcttagaaa tataccgaga ggcagcagt aatcttctt ctccccat 93attga aatcaatgat cttgagaga aaaaaaaaa
aaaaaaaaagag gagggtggga 936aagc aaacaaatgc tggttcattt gtttttaggc actctatgta ggaccacct 942gaat ggtaaatata
gattgttca tttcatttc tctccgcca ggtggagaaa 948ggca ctacagcca tgccttgta aatggccaaa gtatgcttat atttattcat
954aagc cttcgaatt aatatatgg tttaggattt aaggagagga ttctgggaag 96aggaa gcaactggaa agtctctctc cacctagaca
acaattgcac tggcagaatc 966atgt aactactta gaactctgga gctactgaa cgcttgaac ttccagagga 972ggat ggtaaatgaa
cgtaatttc aatccattc agctcttagc acagtagcag 978atgt ctactctaa cccctggca ggaacttatg cacagttcc cagagcaact
984cagc ttgtgggagc caaatgaac aaaaggaaac ttgccctca aactctgag 99tgttc tggtaactgc ttctgaacac agagacgagc
acaaagaggt gggcagccac 996tgta catccatcc cccgactgtt agaagtcct tctccctc ttgctgaagt ctccaga ggattaaag
gaccagtacc ctctctgc cttcatttt tcttttccc gttgggag ccagacatta agtaatagga cattcaaaaa caactgcaca tataggggaa
tagagact gactgcacat atccagggaa aggtcaagc tcagaaaaaa acctgagaag cttaagtt gatactcag gctgatactt
ggcccagaga ctatctaca caataataa ataataat aacacacatt acaaaaaag ggcaaacct agggaaagag gaaaatctga
tccagagt tgcacatta ttgattcaa atgtccaatt gtcaacaaa actcacaagg tacaaga aacaggaaag tatggccat tcagaggaaa
agaaaaatcc acagaaaaa gaaatatt aatagagaca gacaacataa aaagaaacca aatgaaatt ctggagctga agtacagt
aactgaaatg aaaaattcac cagagggatt caagcagat atgagcagc aagagaaa atcagtgaac ttgaagatag gataacagaa
atttgagtc tgaaaaacag aaaatatt aaagggaaca gagcctagaa gacctgtggg acaccatcaa gctgacaaa atacattg
ttagagtccc aggagaaggc agaaagcagc agagagaata tctgaagaaa atggctgt ataattcca aatctggtaa aagacatgaa
tgtaaaccat caagaaacc taaaccac aagtaagatt aactcaaga gatacacaca aaaatacatt atagtcgagc caaaagt
caaaaacaga gagaatctg aaagcagtga gagaaaagct acttaccag aaagggat ctctagtgag attacctgca gatttctcat
cagaaattct ggaggccaga gcagtggg ccaatattca aatgttaaa agaaaaaaa aaaactgac aaccaagaa ctatatec
agcaaaactg ccttcaaaa gtgagggaga aattaagagg ttcccaggtata cataagct gagggagttc agtaccata gaccacct
gcaagaaatg ctataggag ctgcaaag tacaatgaaa ggacactaga cagtaacca aagcagtatg aagaaataaa tctcaaga
aaaataaata

cattgggcaa ttataaaaac cagtattagt gtactgatag tgtgattc cagttttgt tttctatatg atttaagact aatacatttt ttaaaaaatt
 gtctaaat gctagtatta ctgttttaa aaagttaatg aggctagttt taaaacaata accatacg atggaattaa gtcattaaaa ataattcaat
 ctaaaatatt gccaaagftaa gataaaat tgtatacgt aagaataatt cactgtttgt aaatgtgata tgttcatata gcatattc tttcatacat
 acacaaataa tcagtatttt agtaaatttt gaatacaaaa aaaggagt cagcaaaaat ataaagcaga taatagtggg tatatctaag gagtatgca
 ttggatta ataaaaaagc agaccctaaa acaaggattt gcatgtaaat gggtcattca atggtacc aggaacact aatgggacag gaagaaagta
 ggacatggaa gagaagaaag acaaaagg gttggttatt gagcaagta ccatgggtggg caagtggggc tcaatcccac ggaaccc
 tgagtgacaa tgtaagacat acctctgata tcttagccaa aggatgagga tctatttg cccatcccat ccccaaacgt gatggctga
 gatctcaggg acattaact caaccctt ggagcttggc ccacatatac aagtcaaaag aaatcctgca gaatgggagt caggcact
 tgtcacagaa tctgcctac aagtaacgga acaatgagag ctgtggccat aggtaaga cacttgtggc atctgctata gggtgagtta
 tggaaaactg acttttgaca atttttat tgtttttgc ataggaatga catattttaa aatcaggaaa aaaactgag aaaaacac cataatatta
 ggttttctag agaaaagaaa aagcttaca ctaagccccc atgtgcgg ggaggccagg ggtctctct caaagggggc ctccaccta
 ggaaatgtct cacagagc cagcagccct ggagatcagc tcaccgcaca tgccgggggga cagccatg gaaagaga cagtaagac
 aaagcacagt tctgacattt ttattcactg atcataaata gtctcatg agcattaagg tgatcatgaa tgatgtacta gcacctggaa catgaccatc
 ggagcact cactgattcc ccatcactgg ccaagaagt cggggcatct tctttcacc gtgttcaa ctttgagggg acctccttc tgggtcagca
 attttattct tggcttggc aacaatta aaaaatcata aaagactgag tgtttgcaat aaaatatcaa agaggataag gattttct gttcttcta
 aagtctaaag taaaagggg aggtagggaa gaaggaaagg aggggaaa gatgtcaggg atctgccacg ttcttctt cctccagagc
 atttacaaa caaacccg gggaggtatt tattaatgct gtttgagat gggttgcgct tctctgatga cactcag agcttctgg cggccctgtt
 tctgcaatc ctcccaatc acatcctgc gtcagggtg gtaattgtt agccagtcgc actgcaggga agagaaggac agacacggta
 caccacca catcttaac aactggctac acaggtcaac agcaaaaggc cccatgtgct gatcaca gctgagagaa aaggtgtgca
 acacccttc tcttactca caggtaaagta ttcttgt gttctgttc cccggaaata cataggacca gacttcatgg ctctggtga aggtccc
 agaacagttt actattatag acagcagtct ctaagccagt agctcctgct cacctgtg tggcttcat ccttaaacc tgagccatcc tgggaggtgg
 taagtggggg tagccccg gactctgtga gaactcctgc tgagagagac actcgaagct gtctgcca cactgggc tacatatct
 atateactg aaaaagctga ataaaaaact aggatcagcc gccatgg gtgtctttt agttagctg cctagatgaa ccaaaaact
 gcggtggta gactgtgg tgcagcagaa tggcgtggg agtaactta gtttcagac tctcaactca atgccaca agagcaggag
 acaaaaaaga gactgaaagg aaggacctgc tggcaggact gtgctgg gcaggggctg atccactaga catgatggca aaagctctga
 ggcaggaaaa ggtgaact ctctccttg gttgtatag ggaaaagggt aagtctggag tgaagcaggt taccaaga ggacaacaag
 ccactctcat cactgtctat ggggtagct gcttggaaagc atgagact gatagtcca tggctgtgct tgcataaat gactcaaaag
 ccattttgga gcagcagat gttacagaag tactgcttc agggactaca atccagccag gtaccaaaagc agctgggg tccagatggg
 cacacaaacc cattaattac aaggactga gggcagacag aggggtgt gttaccaact ggctgtgacc cagccagggt tccaatcct
 actgagaaga ctagtgc ccttctggg agtcagggaa gtgatggggg caggggagga tgtcaaaagc gcaactg ctatgtgctc
 acagcaaggc cagcagggt acaaaagcag ctactgtcca gcagctca acagtaaggc aacggcagca tcttgggtga agcctggggc
 cacagccaaa ccatggc cttttgggtt ggaagtaggg agggaaaagt gggagtgtgg acagcctcgg gagcctga ggagcagcag
 aaggcctga cagtctcag ctggccatat tcatatctga aaggtcct ttctgccc atggtgataa gtgatgacga tgcagacca
 aacaaaaac ctaaagt gactcaaaa taaaggctaa atagtaaagg gcaaatgacc agatatttta agccagat atttaagaa gacattatct
 gccctacaaa gactaactgg ccgaaagaat tcaatca tgtgggcatg caaggtgcag caatgaaca ctgggtaaca cagatccctg
 ctatgtcc aatgtcagg gagtagactg atttctctc gaggaaaaat ggctggctt acttctc atatactact tccctggata aaggggaatg
 tcatatggga gaaatgcctc gatgggta cactttatgt ggacaggaag gactgcatga cctagaatta ctggcagga ccatagcc ttggactcc
 aagagtgcga aatgacttat tactggaaag cccctgcta tccctgga agctgtgcc aaggccatt acaagagaca ctggttcta
 tggggcagag attetaag cagggtgggt cccatgccc cctatgtgtt ttatttct ctagctaag aacactta caggggctgg acaagagccc
 ctggactg gaaggactct tctgctgaa gacacacc agacattgtg ctgataggt gagtttctt tccatatec atctacaagc cataacc
 accgggtatc agcaaggccc atgtgggtcc tgtgagtgg aatgtttagc aaccaagg gcacggatgg ttaagcagag gcgtcaagc
 acagaggaaa gctaagcagg gtggatgg actttctcat caccacctg tgaactggaa caggcagaag aggttctag gggagaat
 cccattccac agctcctgtg gaagggaagg tcttaacce ccaagacc tctttac agtgcaga acgaggcca agtggggcgc

agtgaggaaa tgttctgcc gagaggca ctcaaaggcc attggctgcc tcagataaca aatattctt attccgagag acccaccg tgcttaccct
gccttcggct cccaccagtc atttgctttt cattggaact tgaccct gccttgctct ggaatttg tgctctggc tccagcttc ctggttggg
ctgtttg tctgtctagt gtaacagtt cctacccat ttctgacct tgtttctgct gacctga acatctgtgt gattctcag gcctttctca
tgteccagg actgcatct cctggcct taccagtcca gggctgaag gagttaagac ccataaccct ctgagctggg agtaagca
ctgttgctcc ccaggcttg tgaagggtt cactgcccc gagtgaccac tagtaacc gagaagggt ggtactatct ttctcttctg ctgtgtgaa
acaggacata ataataga tttgcttct ctttctta atgttctatg taacacaaga aaacaatctg atgtacag tggccaagag gccccaccat
ccatctggct tttgtaggg acacacatag tcatattt gctaaacag cctcactgca gctatggagg aatagtacag ccaacaatg atacgagt
tccaccaca aaccctacag cccagaatg gctgcgggaa acaggactat ccacctgg aggccccaca aatacaggaa aagctcagga
gtcctcagaa aacctagggc tcagactc aactggccta gacctctaaa tttaaaatt acaaagttag actggattag aatttagg attagagga
tggattagaa ctatttaagg tagtctccac ctcccctagt catgctg cccaccaaga ctccccatt acctcttctg ctgtaagaga atccacatct
cattttgg tctgaattgg aaccaatgtt agaggttcaa aggtcaggct tccccgtta aaaattat actgcgggag aaagaagaaa acagatgctt
ttactctct ttactatgct agcaccat gaggtcattc caccagcatg ccacctca gagccagggg taactgggag aagaagtg gtgagctggt
caccacttt cacagacaca caaggaacct gatgccattt caagagct cctccactgg gcaacaatg gcctgtgcca tcaggaaagg
ccaaacaag tgctgagg ggtcccagc aacaggctcc aaggctaatg tctactgtga taggaaacag gcaggata tgggggtatc
tgggcttagg ggcactctg gtttggttc tccaggatgc ggggtgaa gtctcaaaa ctattttat aacagtcaac tgtgtggtct gccttgacc
ccaggccc atcaggcgac aacacatcta tccactggag cacacaagaa catgtcgggt ctgttcat ggcagctttt gggaataaga
tgggaggtca ctccaagaa tagtgacttc tgccaaag cagagagcag atccccgcag ataacctct ttagacaca ggaagctact
cctcaat tgttcaattc caccaatgga ggaggcaca acaggcttt taggtaaagc agagccta aaacctgca acctggtaa cactgatggg
ggaagagggt gaaacacctg ttgtattg ctttgaggc tgacctggtg ataactcagg gttctcaac ttacctaat aagtcacc tggggagtgt
gacaaaatta cagctccag gccccacc ctggaaatc gggctgag gaggggacct ggaattagc gccttgaata ggcaccctca
gcagaagaga acaggccg cctatagtaa actcagagcc ccaaatcatg tgaagcaagc atcagcctga gtctgtga atcccagtc
tagatccag tcattaagg atttcttctc tggctttgca gaaggagt gtggtttcca ggaaagtccc tgatatctgg agaagaaggc tccatgttg
ccagaatg gcatactctt ggtccaaag acattaagtc ttcatctcc cacactaaga caggaaaa ttttaagct ttgcgagtg gcagtattgt
agccaatgag gtctatccga cgtgatta ttgctaataag aacaggaaa attttttaa taaatctca ccttggctt caggaacc acaaggaca
cattctcaat gcgaattca aaagcccat ctctatagta cgggctct aaaacaaacc aatcccaa aatgagaagc agcccacgat
gaagatgtct agagagaa actttcactc cttggatgac tgcctactc caaaggagaa gaaacgggtg gagccac tctatctggt
gtaagagcct agagatgcca cttctctca tatggccact ttatagg cacttgaggt gcagaaagct agactctgaa gtccctgcac
actggctaca gtaaggag taaagtaaca gtggatccac taaataaatc atggttca tccgtaagac aataatga aggcattaaa atatattac
aaagacttg caatgacctg agaaaaggca gtatcaag taagaaagca gaacataaga caagatgcc agtaagatct caatgatta
aaaaaat gctatctaca tacctgaaag accaaaagct aatacagtaa aacactaagt tgtttccc ctgagtgtt agattgcaaa tgatttct
ttcttttta cacagtccc ctctttt ttctaaaatg aacatgtatc agttctataa tcagaaaagt ttgttgaag aaaagtat tgccaattta
ctttaaacta attaaaaaat acaaaacaac gaatagcttt aaaaggct caaggatcca cgcagcct ctatgtgagg gacacttacc
atcagtgaca catgctg cctccaagg cctcatcagag aatgtttgt aactgatgcc gcaaggacc atggacat tcaaaaaaga
cccaacacca tgtccagtc cgtgcaagta atctaggcct atccata aagctgaac ggcaaggag tcaagaaggt gacctgaaag
acataaagag acttaatt gtattgtac agcgttttag agattaaatt tattatgtgt gcctccagaa tgaacag aaaccaatag gtaagttact
ggagggttca gattcagca cagcacaagg gaacttc taacaatcag agctcctgag aaaccatcag agctcagct gaagctagc
tcatccat tcaggatgct ggttagcgg gatagacacc tacagcacac agaggccgta agacatgg acgttccct gccagctctg
cgaccctaag gttcagaat taaaagatg actctaac cagactgca gcagacaggc aggcagatgca gatgaggaaa ctgaggccta
gagatgag tacatgtcta atctaccaa aagcaaggca gccaggtct tgcaatgcc gtccaatg ctccaccac caggcctca
gcaaagtagt acatagctga agtcagggtc agtaaaat aaatcctaag aatccccgaaa ggaagcactg gccagctact aaagggcaga
ggaggctg caccaactc cactcaggcc ctgtgacctt catatctggt ttgtctctc gggagcca tccatctg tcatccaata ccataagtg
tcaggagaat ggtgcacagg gtactggg ccaatccta accggctcc ctgaggcctc tgggctcagt cagtgggtta gagactca
ccccatgagc acctggctgg gctgaagtg ggatggggac ctacagtg gaacgaca tgttcttca ctcaacata gacatattg

attctcaaac aagaaaaaga ctgccatg tgacagaatg caccacctac ctttgggtcc agtcgggaaa acggctgcac acagctat
 gtggcccttg aggacatatg tgaagcattc ctgcaaagaa aaccagggg tgttgacag aatggggaca gatgtctaat cctgtagttt
 tctgtagtt cagaaaatcc cctgctaa agtttttagc aatatcatag agaaaatgta agtaaaaaaga aaaaaatctg ggaaaaaa agcctggcca
 cgggaccaat ttcccagaaa atcttgaat tcaatttagt aagagcac tgtcagagag atgacccac atgactttat aatgaacact ctgacatact
 atcatgtg agccttagaa agaattgaaa agtaataaaa agtactgatg accctagcta attactga gctatcctct gtgccagca ctattctaag
 cactgtatgt ttgatccac ttcacgat ggaggcacta ctgttatct cgttcacag agagattcag tagcatgcc atcacaca gtgcctaagt
 ggcagcatct ggccctggag ccaggcactc ttgctcaac ctgtgctc cctaccacca tctatcttc aggggttate cccactgtcc
 ggacaagaga 2gctactc agaagtgtag cagcttgcca gtaagtgca gagtcaggac taaaactcca 2tctcag cctggttag
 ctcttgaaa agcacaataa gagtcacacc aaaagaatcc 2acgcaag gtccaaattc ttctaaggca ctggtgaata caaatggaaa
 aggcaaggga 2agacaat gaaacctgcc cactacatt gcataaaacc ctttcttg gataatctc 2aaggagc tctctggac aaacagattc
 acttaggtgc tcaatcagca tttgctgagc 2gactatg atccaggaac ttgctgggct catgggaatt cacagccacc cgggaagggtg 2ccttta
 tctcatttt tatggatggt gactgcttg ttaacgtca cagagctagt 2tggcaca gaagctctga agccaggtct ccagaccct agtacacatc
 tctctgctc 2gctctct tccccttc catgccaatc ataccagaaa ctaatagag tctgtcattt 2aaagttt ccagagagtt aagcctgtaa
 ataagaatct caaaaaaga agggggtggc 2caaaatc aatctagc actgctata aagcatgtat tcaactatct catccccagc
 2aaaggca tttctgact caagagaagg ccaagctac tatatttaa cttacacctg 2tgcctc accttagcag aatgcttaa aaattctc
 aatgtctta ttcaataat 2ttaatg aacctgtaa agcagataag cctgactcca cagcaaggag caattttact 2ccccatg taattttac
 ttctttatac aatccccctt cataaaagca atgctctct 2gaaagca gagaggacct ctgagttt ttacctccac cttacctct cgtaggctgt
 2gggtcca aatgcattg tccgctc acatctgtg ccatccctt ccaaaaaag 2aaattgg tttccgca aaataagct taagcaaat
 atgacacagg caagcatgtg 2aagtgag aagccccata caatgctgt gggcatgtaa aatagcacag ccatcttgc 2tagttc
 cagttctta aaaggttaa tatagtcacc atatgacca gtaattccac 2tagttat ataccaaga gaactgaaa catacatcca cacaaaaact
 tgtacatgaa 2tcacagc cacattatc ataatagcca gaagatgaa acagctgaaa tgtccatcaa 2atgaatg gataaaciaa atgggggatt
 atccacacag tgcaatacca ttcagtaatt 2aagaaat ggaatactga tacatgctgc aacatggatg aacctggaag acattgtgt 2tgacaga
 agccagacac agaaagccat acataataca attctattc tatgaagggt 2aaatagg caaatccata gatacagaaa ggagagtagt
 ggttctccag ggtagtggaa 2ggggtag tgaccgctat tgggtatgag gttctttt ggggtaatga aatgttcta 2ttgattg tgctgatggc
 tgcaaaactc tgtgaatata taaaaaaaaa taattgtata 2ttaatg ggtgaattac atggtacata aattttacc caatgaagt attttaaaa
 2aaaciaa gtgtgaatgc agggatggct aataaaactg ggagtgact cagcccctga 2acgcatt ctgggtctac agcataaggg
 ctgtttcag agagacacta tcaactgggt 2gaacaag acagaagaag gcaagaaaa caggagcca tctctagcaa aagaggcca
 2cccaact tctctgtta gaacagcagg gggttctc gacagagacc ctaaaaat 22gtacat atctaacac aactagact ataccctga
 catagaaagg ataacttcta 22cctgct aaaaatttag aagtgaagaa aagtttacac cattatcaag caatccttag 22aggctg atattattaa
 caccctgtg tccaaggcc aggcattggt gccacgtaat 222gagct cattcaataa ttaggctc ctttagccat agtcccaact
 tcaatgggga 2226cagc actaaaagg cttgctcggc tgggcacagt ggtcagcc tgtaatccca 2232tggg aggccgagc
 cggcggatca cgaggtcagg agatcgagac catcctggct 2238gtga aacctgtct cactaaaaa taaaaaat tagccgggcg
 tgggtggcggg 2244tagt cccagctact tgggaggctg aggcaggaga atggctgcaa cccaggagc 225ttgca gtgagccgag
 atcacgccac tgcactctg cctgggctac agagtgagac 2256tcaa aaaaaggcc ttgctcgtgc cctttaatg cagacagggt
 ctattctac 2262ttt gggttccgta tcaagacca accaaatctt gggttctct ctgagaaact 2268caga gatgatagcc gtgaaagcag
 caaacatgg agaaagaaat tcagaaatgt 2274agcc ctattctc attattcat tcaaaattaa tccctact cataaggccc 228cagct
 gagagtacag ggaaccggca ggcggttcat gggctgggt ggaaaactt 2286ttcc aaaagcttgc ttacttcac agttgttac ttattttt
 aaaactcca 2292gact gtaacattc tatcaaacag tctttgtga gaacagagtc acaactggc 2298aaat aggggtgaaa
 aaaatgaaa gacacaggaa cgattccatt agtggccagc 23aggcg atgaccagct gagtctctc agctggagct cagctgtcca
 cttctccac 23tcgaat ccatagtc aa gttccacagc agtctggtt tactacttg tattgagc 23gtcaat aaggtacac tcatccaggg
 acaaggtct atctgtc gggactggc 2322agtt aattaaat taattatcc acaaatgaa acacttagt aatctgggag 2328acac
 aagagctct tgactatc ttgcaacta cataagcctg aaattatc 2334gaaa gttatgcaat aatgaattat tcaactaat attaaactc
 tactttcaa 234caatc aacctctc cccagctgag ataaagagct caacaaggaa aagtaaacac 2346ttat gtctacctct gttgtgtct

gaaacaaaat aggtgttcaa gagataattc 2352ctaa aaaatgaga acgattagat gcaacaggac cttagctagag tcttgggaac
 2358agga gcagcctgga gtcactgcag cttgcttgt ctctgggagc cccaggcccc 2364agcc tccaggcccc tcttcagcc
 ctgaccccag caggtacctc cccactcgt 237gactg ctgacaggc aggagtggat gtctcaactt gggagaaaaa ctaaaggaat
 2376ggga aaaggaatgg atcacgatat tcttctgctt caaacaaca tgaggattt 2382agtg atctcttcc ccacaccgt ttcaaaaca
 tactactgca ctgggaaaca 2388ggga tgagagcact ccaagtctt gccctgcagc tgaagtgagg ttgtctcca 2394ggta
 ccaccccctc tcagcaata agggcaccag tccacacaca agctgaacaa 24aaaaga caaccagtac ctccagaacc ccgctctaa
 acaggcttc aaccaccac 24aagaaa tgccaacgca gaggcaaatt tcttccactg gcatgaaact gtttaattg 24ttatac ggaaaattc
 aggatagat ccagccagga aattcactc gagttaaaca 24ctgaag tcctctgat attttatgc tggaacagaa gcattaagt
 aggaaactgt 2424ccat ctgtgactgt ctccacaca cagctcaaa atctgcccc agactaaaag 243aaaac aattattaa
 agggggaaaa aagtgtgtgc ccaagcacag tgttctttg 2436gtgc atgtaacaga tgggatgca cagaactcaa aataccagt
 gcaaagcaaa 2442tgaa ccaggcagag ctgaggctga agcccaatgg ccacaccta tgacattcc 2448ctcc acaggaagat
 ctgtcagtc tagacatc agtgccccctc tgtctcaaa 2454gagg ctggccctg tgggtccatg ggttcttga gaccagtgg
 taaaaaaacc 246ctggg atgccaggct tcaggctcag ggggacagga agagaggga ctgattatc 2466caa aacaggtgc
 ctcaaacct actactaagt ttttttgg tatggaactg 2472ctca caagatgat ggactagtc aaaacagctg ctgttacc aaagaaaaac
 2478aaaa tccagtcag gggccaagca cagtggctca cacctgta tccagcact 2484gctg aggcaggagg attgcttag
 tccagaaatt cgagacaagc ctgggcaaca 249agatc ctcatctca caaaaaaac taaaaattag ccaggagtgg tagcacatgc
 2496tccc agctactcag gaggctgagg caggaggatt gcttgagtct aggagtcaa 25gcagtg agttgtgat gcaccactgc
 gctccagct gggcagcaga gcaagacct 25ccaaaa aaaaaaaaaac ttagtcatca agatgcaagg gctatgata cagttcctgc
 25tcaaaa aggaaagagg gacaccatc tgactacct gcagagaatg ccagtccat 252gccta agaagaggct ccaaaaggc
 agaggcttg ggattgggag aaaataaat 2526agtc ttatttcc tcttttaca gtctcaacag acagatgaag gtgggcacag
 2532ctgg taaaataatg tctctccc gctcagctc ctgtgcagaa gcagcaaggc 2538gcat gctctcgc atgcttacg
 cgtagtgaat gatggcgcg ttgggtccc 2544aat tgttgggaag ctcaggtcca caagtctgc ctgttgcctg taacagaaag
 255aagca gagggtta aaggtttta ctgtgctaag atcagggcc ctccagct 2556acta gcaagaaaat cagcagagg
 ctctgggct ccccaaatg gatcctacc 2562actc ctgagcttg tcagcagctg agatctctg cacaccact ttgggaacct 2568aat
 tcttataaa tcatctggtg agataatc atgtgtgct cttacaaat 2574ggta cattaanaagc tctcttctc tcaattgct tctccaac
 tgaccaatc 258acaca tcttagcaa gggagaactc ccaaggtc taccnaagc tatctaaaat 2586gttt ctattcatt aattttc
 tcaactattg tcttcagta tttatccta 2592ccca aaacaata tctaagtta aaaattcaa agcatccct ctaagaaat 2598aaga
 aatcattct agagaaataa aaaagataa tgcggagaga ttattgcagg 26ctgata acagcaaaaa attaaaaaca acccaacat
 taaaaatag gaggactggg 26taaact agaagagcca ctgatgcag tttcattg gatccttt taaggctca 26acatgg aaaatgtca
 cactatgatt ctaagagaat aaaataaac acaaatcat 2622gcca ggtgtgatg ctcacacta taactagc acttgggag
 gccaagatag 2628cgt tgagccagg

agtttcagat cagcctgggc aacatggca aaccttatc 2634aaaa atcagaaaa atcaggtggg ctgtagccc aactaatcg
 gaggctgagg 264ggatc acctgagctt ggggaggctg aggtgcagt gagctgtgat cacaccacta 2646agcc tgtgcaacag
 atgagacccc atctcaaat aagaaaaaa aaaagaaaa 2652atc gcacactaag agacatgta aataattta ttttttaa
 aataattac 2658gcac ggtggctc gctgtatc ccagcactt gggaggcca ggcggcgga 2664ggtc aggatcga
 gaccatctg gtaacacag tgaacccc tctactaa 267caaaa aattagcaa gcatggtggc gggcgcctgt agtccagct
 agtcgggagg 2676cagg agaatggcgt gaaccagga gacggagct gcaatgagc gagatgctc 2682actc cagcctggg
 gatggagcaa ggctctgt caaaaataa aaaaataat 2688gta taataaat ttacataag tccagcatg gtggctcag
 cctgtaatc 2694ttg ggaggccag gtgggtgat cacaaggtca ggagtcaag accagcctg 27gatgt gaaacccat
 ctctactaca actacgaaa ttgaccaggc gcaatggcag 27ctataa tccagctac ttgggaggct aaggcaggag aatctctga
 acctggcag 27ggttgc agtgagcca gatcacaca ctgactcca gctgggtga cagagtgaga 27gtctca aaaaataaa
 taaaataaa taataaat aattacata gatgaacaat 2724aagg aacatgagg gaaaaagta cactagggg aataagaca
 atatttct 273aatta aagagtgt tatacaatac taaaggga catgatatt ttaataaca 2736agaa accacctct gtcaactag

agcaagaaat taatggccaa gactcaattt 2742aaaa ggctcaaggc ttaaactgaa gtcaaaatg tacacaaaga tcttttctc 2748caat
 cagcttgccct ataataatat tataagactc attttccctt ataataagaaat 2754tagt tatgattccc taacccaaaa agcatccact ctattatgga
 acttttctc 276tgga ctatttcat aattaaagga atttgaatc tacaccacc aaatttccat 2766ttat taaaatagac cccaaaattt
 gatgaagatc tcacatctta gagcaagaaa 2772gcca agagtcaatt taatataaaa aggetcaagg cttaaactga agttcaaaat
 2778aaag atcttttct ctaatacaa tcagcttgcc tataataata ttataagact 2784tccg tataatgaaa tccgcttag ttatgattcc
 ctaacccaaa aagcatccac 279tatgg aatttttctc attcttgta ctatttcat aattaaggaa tttgaaatc 2796cacc aaatttccag
 agagaattat taaaatagag cccaaaattt tgatgaagat 28gatctc atggtcagca gagcatggga gatgcttaga gttagaatca
 catatagga 28tgaata atgtatatcc acatattaa caaagactaa gaaccaacct cttctccag 28ttaaag agttcacaga gagcaacagc
 atctttaatc tgtgcaaca atggagacat 282aagtt atcactgaaa atcacgtgac cagattcaga gcttagccct aatgcaatac 2826ggct
 gtactgcag ggccacacat catcagcaac cagagcttta catgtggaca 2832ggaa gctggtgtgt gcagcaactc ccattatcag
 ggaaaggctc ctctgctatt 2838ttca ggtacaatca ggaagggccc cacctcagag cacagggagc tctccaaaa 2844ctta
 aaggtaaga accctacagg ggccaggaaa aacaggcca ctatcaaaag 285tctgg gcccaaaatc tttctcacc agcatcact
 catcaccatc atctactg 2856tcaa tatctcttt tgtattgtgt attatacttt gtaaagatct aatccatcaa 2862tatt tcattcctc
 aataactcct cctggaaggc caggaggctg aggctcagag 2868taac cttgtgccag gctcaatgcc acagaggagg tgaaggagcc
 gggcctctg 2874tcaac atccatctt ctgcaccagc tctctactc acgtgagccc gctcatgcc 288actca gctgaattct tcagcttt
 ggcgatgcag atgggggtgt aaggcataca 2886gtgg tcttagagge aaagggcagt aggggtggaa atcaaacgg ctcaccac
 2892ccaa ggcaacaacc ttttctca gcaaaactta ctttagacaa atcattgaa 2898ccac tggegacca tatagctatc
 cctggggcc ccaacgacct gtcctttt 29atgacc ctgagctta gctcaaccaa aaagagtaag tacatcaaac aaggtgtctc
 29ccatcc ctactcct tagctctttg agactgctgg ctgctgccc tcagcaagac 29cttcc aagccactgt ggtgtggtt agagttcact
 aactgaaa gcttgaccga 2922cctt ctctgctgt acaaggggg cttttctcc ctgtctagcc atgcacatga 2928gagt gaggtctct
 gctcctccc tcccgccca gtggtctat ctgactact 2934aatc tgatctgaa gggctggaga agacccttc caattgaga
 acaagttaga 294gcaga ggggctcag cacactggc acttgcaaa agcttctaaa attgctttt 2946tate tcttttctc ttctctca
 gagagagagg agagagagag aggaggagc 2952tgtg tgatgatggc aggggtacaa tggcaagcca gatctagaga gccaggcctg
 2958tccc aggatcccc actgctcagt ggagaagaaa ggacatcact gggcttgcca 2964actt ggagccaga ggcccagggg
 aggacagtag aaaagcctac ctttaaagag 297gatc cagtccatc tcagacccta atgaaaatga ggcaacaagt gtcagctgct
 2976tgcc cagcaagggc tcagtaaagg gcaaggetat cactatcact tgaattgac 2982ccaa atcccact ccccaatct
 ctctgagcct caagtctct tagctataaa 2988tgcg gcagaaggag ggggtagaga agcatttccc aagcttcaag cattctata
 2994gcac agctttacc ctgcttctt aactgctgta ccttattca cttagtactt 3tttagac catctttaa tcagctttat taaattcaac
 tttatttaa ataattat 3gaactca tgctagttat gtttttcta ttatagcta aatgctgta aacagatat 3taagtaa acctaaata
 taatgtgtac cacctaaat aatctctcat gccactct 3aacaca agactcaaca agcaataagg gccctcagge tcttctatg
 gctccagctt 3ggctca tccatggaga ccacagttct gatccaacag gcagcctcag aaatctgct 3ctccaaa gacaataca
 gaactgggaa ggggggtggca gagtttagat gggccaaagt 3gtacca acctgggga tggctcctc cacagcatag ctggcctgt
 cactgacca 3cttctc cttggggaga ggtcagcaca caggccttg agctcctca ggatggactt 3gggatgc acctggatcc
 tgtattcggc tccagacc aagtcaagaa gcaggtgctc 3cacactg ggggcgtcta tgcggtcacc atcaatgaag agcctgcaga
 tggaggagag 3ggtggca gaaaaaggag ggaacatgag tgagaggtg caacacagac acacatacac 3aggetct gttctggc
 aacaaaacc aagcccttt tetctctcc cactccttt 3aaatct gccctcaag gtgcattccc tgeccctc caccatct
 gccaagccag 3ctgggc agtctctcc ttcactgat acctctcc cgtcttcat taagacttg 3cccacag cctaaatct catctaatct
 gtcagctca tetacagcct cggcagta 3ctcaggt tcaggtccca ccatctctca cttgggttag tgccacagcc tetaagtct 3ccatca
 ccatgctt agtcataata tctttacaa cttgtacatc taacatgtgg 3cctctga aaaatcggt caatagctc cactattct tgtcagaaa
 aagaaccaa 3cctgaat gtggcccaca agcctctct tttctgtgc cctgctcact attctgct 3tatgtc tgacctcact gaaccttc
 aggtctcca catgactgt gctctact 3cagagtc tctgaaatg ctgttctc tcttgatc atggttccc gccctctc 3ctgcat
 tcactaact caccacatt tctctact ctctgctca aatattact 3ccaaga gctgctctg atctcaagt ctaggcagg ccctctct
 aacactgta 3gtcccac aagcagactg gtgcccactt atgtgccc aaactttaga aagaggacat 3catctcc ccaactccag

ccaaggacce cgtcctgttt cagtcaccct agcacctaac 3gaccett agcacatcac cagcacttaa taaatgtgtt gtcttaatgc
aaaaagctat 3aatagaa cagtaatgaa aagaaggcca cacgaaatgc tttgaaaaaa taaactgaca 3caacaaa gcgtagttgg
aggggtttc ccatattatt tttgacctc aaaatgactg 3ttatttg cattgtggac ccagaattgt ataattgagc atatataccc cttaacactg
3gctagaa aacttgacat caaatgggtg gcccgaacta tagacacttt catgcgttc 3ccatttt gggggctcaa agagaggcag gatataata
aacacctact gctaaggaaa 3agaaggg aaaatgttaa aagggaaga aaaaagaagc acatcagtga aatcagggc 3gatgggt
gggccaggac cagaaagggc aactagggc tctgaggagc tctggaaggg 3tccagat gcagggcaaa cactcacatg atcgtctcta
gtcctatgat tgcgtaggag 32atactg gattgtgctc cacatctgat cctcggagat taaatagccc tagaaaagaa 32aatcc ctgtcacctg
tctgacttaa gatgtaagg ggtcgttgt agcgggaggg 32gcttca gcttgagtc cagctgctgc gcaaggatc agtggatcg
cacagaaagg 3222gcct gactcccgtc tggttccacc tctgagctgc aattgctcat gtcaccacg 3228cacc agagctgttt
ctcaggctc cacatcactg cccggagaag ggaataaaag 3234gttg aaatcctgag aactgcccc acaaggagtt gaaatgatcc
acctagtgt 324gccag gctggcctt gaagccgaca aacctctgac gctcccaat aaaaaggaag 3246agca ctctctcct
tctgaggcag atgacctagg gtagaaaaac tgagaccctc 3252ggga agccaggcaa gctcctctg taagggtcag tgagccccat
ggagacggag 3258gtca gaggtgaaa gaaaagcagt gactcagca ggctgcagc caccaatgaa 3264gcct gcagcccacc
catgggtctg ctctggcacc acgactgggt gggggacctg 327agcca gtaacagtga tgttctgaa cgtctgagaa ctgacagac
caggagagag 3276ctg gtcccaggac tccagctc cgtcactgt tctcatgagg atcagagcaa 3282gcct gggcattaaa
agtataacct ctattttaaa ataattgctt cttaaagtga 3288acca tttttacct atcactag cacttctta aaaatgacag tacctgtgt
3294gtgg caagacagac aattcaaat acaaaggtgc aactttctg gcagacaaag 33agatga gcaaaaagcc ctaaaagcca
accagaaata ggaagaaat tatcaaacac 33acatgg atcattgaac caagatttg atgtagcat cataataat tacaggatta 33aataa
cccaaaggc atccttaggg aacagttaa ataaattatg gtataaccac 33tggagt atttaact cacttaaaat tatgcttga tatgcttata
gtgtactgat 3324aaaa aatcaggcta taaatgata tatgcataga atattgacac tgattatctc 333aacag aatttatac tgatttttt
tttctctt ttactctc tgcattttc 3336tcta tcatgggatt gtgttttgt tacaatcagg gagagagaaa agttttacag 3342ttct
ctgacttga gatcattaag ttaattagg atgtaagtca ctgacacact 3348tgtt ttgtggatgg aagatgcagg gactgaagag
agaggacact gcagtaggt 3354ctct agtgagaagg caaaaagata aagcagtgc tctctcagt tgcctgggt 336ccact
cagaaaccag aagacaggac aggaaggctc aaccagatc cgtcagggtt 3366aaag aaggtgctga acaactgat gaaggtgggt
taaggtccaa agactgagaa 3372atta catcaagggt cttggggagg aacttttagt tctagtttt ctgaggtaga 3378ccca gaacattctc
actataaaga ccttaggaaa ccacaggaca agtgtaaaga 3384gcct ctctatgag cccactteta cactacaga ggctgacaga
cataaaatat 339ggaaa tgccttctc cagaggtgc atggtctga gggactggcc agaggtgggc 3396cagc tgtaactg
ctctggaaa gctcactcc cctcccagc tctctgtaat 34tctct tctctatgagg tggatctcc tatacccatt tggtagcga gtctctct
34ccctgg cactcagaa agttgaatgg catgaacaca cagatacca gagacccaaa 34agatcg ggtaacatgc ccaaacagcg
aaaccagagc actcacagc aatctcatcc 342agtga ccacaaacca catgacgttc ctctcagcca tttcaaccg aaggtctgca
3426tct tccaggagat gctgcaaga acaaatgtg cttaactcc agcctggtc 3432agcg gtaggaacc agtgaaagaa
cctaccctaa acatcttaa tcagccat 3438cagg agcacgtac taaacagcc agggagctg gattcaagcc ctatacaaga
3444caag ccaattgact gctgtagcc ttgattgct caccagtaa atcattcat 345catcc cacaaatgct tgtgtaacat ctgactgctg
caggcataga tacgtgccag 3456tgct ggtcactgtg gttacagatc tgagccagac ccagtcctg tctctatggg 3462aata
tagaaggga gacagataat taaaccagca ataacacac tactgtaaat 3468gcaa caggggacac acagggacct atataacac
actaccagc aaagggaact 3474gtct caggggtcag gggaacagca cccaccact gatgttctg ggggctgcaa 348gcctt
tcagtctaa gacctaggaa ttcctgtag tctgactcac tgtgattacc 3486aaat cacactgct ctctcagaca ctgccaagcc ctctctgtg
ctctgcaaga 3492cgtg gtgtagagg agctcaccct attgccacca caaccacct accagggcag 3498taac tcagggaaca
gccacctgt agcagggtg gctctgtct tattactca 35ctcga cagcactctg cagatagtag gcacccaaat gtgtactgaa
caaaagctt 35gcaaca tttgctctc cctctctat aagcaacaag tcagagctc tctctatg 35aaactt caaacagc tgatggaaaa
tatttagctg acctgggccc actcactgga 3522ctcc ccattcgcga ataccctct ggtgaggatg tcacacaaga aagcaggctg
3528cccc cacaccagc gctgactga agatcagtc gggaatgctg ttaaaactt 3534gaat ctaggctgct acgtttctt
cccaggacce ctctgggcaa tctgctaca 354cagcc atccccatc tactctgtt tetacagca gacgcccctc cctgcagccc

3546cagg cctctctc tgccccca ctgctcataaatccacaca atggttcaga 3552gctg cttaccate actatcgcac
aggccaagga aacacacca caccacaag 3558aagc agaaggtaca agatggagga caaaggccta ggaaggtaaa tctacaatg
3564taag aagggaatg gaacctaga acctctatgc tctatttcca atatcaata 357gagtg gcagttagca gctgagtgga
taaaaaaac ttagtcttt cagcagcacc 3576gcca cccaacgag ctttgcgaaa ataaccaaag ccaactaag tggcaagtag
3582acag tggaacaaa caaagctct gcttctcaa ataccact ggggcagagt 3588aaat cctctgtca gctccaact
gacttgatt cggaggacga ggttgagac 3594aaga ggtgggggga caatggcagg ggcctgctg ggcagaacca ttgattctga
36tgtaat ccaggcccag tgtaggaga ggcttgaag ggcgctcagg acggtctgtc 36tttgt caacgaggtt cctctgaca
ggaatgaggt gatggcggc acttctcaga 36tgcca tttctcca ataactgag gagacacatt gtggcccagc catgagccga
36ccattg cagcagggca gggagcagg cttgaaagt ccagaacct cagaaagtg 3624ccat ggcccagagc tgggtgtgca
ggataggaa ctgtaaaagc acatctcag 363gtgga acttctct taccctgac ctctactata aatcagtc tctgagccc 3636gctc
cacaccac aagcaatga ggagaatga ggggaatca gaagccact 3642ccaa gcagaaagg accaagctca ctacctga
ggaatgata aggggtccac 3648cctg gactctcag gaagcact caccagccag tctctgag ttggtgtc 3654acct
acaggggaa gaaatgata gaacaattc ccagtgggc cagctcatt 366accag aaagataca ttcttaaca tcatgagc
agggtctta ttaagcagct 3666aagt ggattgacag gacttagaaa atctgaacct ccttaacc tggaggcta 3672ggga
gaagtgaag ttttgtga tgaaaacat aagacaagg tgagacaga 3678aaag tatgatttt cactgacc cttgtaaaa tcttggg
atcactgcca 3684caca tggcgtcacc acaagattg tctctcagc gtcagtcac tccccacta 369catt gatgagaatt tggcagtg
ttggtgaag tctgggaact gggagactcc 3696tcac ataccagga agtgataac atctcccag tccccccc tcatgca
37agggtg gccagagaa ggcgctcc ccataaccag cctctgaata gagggctaag 37agtct ggcagcaag agatcttc
gaagattta agagaggcac acaggcact 37ggtgt cttttat ttattact ctgaagacag agtctcact tttatgag 372agt
ggtggacca tctagctca ctgaacct caccactgg attcaagca 3726tgcc taccctccc aagtagctgg gattacagc
tcaaaattac catgcccag 3732tgta ttttagta agacgggtt taccatgtt agccaggtg gcttgaact 3738ctca agtactc
ccactcag cccccaaagt gctggcacc ctgtgctt 3744gagc ctctgggtt ccaactccc aggatgagac agcccttct
gttttaaga 375gcat aggacact atcagctcc agaatagaac taaattact tctatagtc 3756cctt taactaagc caacactc
catatctagc cagttatct tgaatgtat 3762tta accaatgagg tttggcca acaattaaca tctgataaa atatacat 3768agta
aaagttcaca tatttaaaa cagtagaac ttactttac ttttctct 3774tact gataacca cataaccata gaaggaagt gcaaggtt
ataaagaag 378catga attcaattc taaaaactg ctagaagct gacattgagt ttactctg 3786attc ttctattt tttcaaac
cactaaaca gccactatt aatagctt 3792atgc ctagtacac tacataat aacttcaca gtagaagc atgctattc 3798gaca
gatctcggc aaaaccag gtagaatca ctactggc aaccaacc 38gaatct cctacacag aagactgac tgaggaaact
aggaaggagc ctggaggaga 38gactca ctctctgc cacccttg ctgcccata cctacatta ggaacaggca 38gtgtt
gcgctctga ccccaaat gtaacagac ttagagctg gaatccgtg 3822aaga gagatgctg ctcccagg ggcacaatg
atctactgg tgcaagaaga 3828caga gcttctatt gtattatt ttataaaga aattacaag ttagtttt 3834ggaa tataggaa
cactagcaca tataataac aaataaaca acatacat 384gcggg tcttgact ccataacag aagcacaca aaaaaaat
ttaaaggcca 3846gtc cattataac agccagctt aatgctgc cttgtgtg gtgtgtgt 3852gtgt gtgtgtgt gtgtgtgt
gagagagaga gagagagaga gagagagaaa 3858gaga aatcaactgc agcaacagg acaactct agcttgggt ttttatatt
3864atga ttttgagaa atagaactt aatcaatgc caagacaaa atgttctt 387ccca agacaaaga cacatgtgtg tttatgtg
gggtgtgtg cactacctg 3876caca cctcagc agctgctgc ctgactca aggtatgt ctactctt 3882gct
gtgactga ggactttt ctctctat tttctac aacaacaag 3888cagg ttttgtt catctctt tctactg gccttctt
atctctgt 3894gtc aaaactcagg aagcaagac tttgactc cctaaaacc gtgttctaa 39tattt aatgacagga aatgacac
ggcagaaa taaatgaaa cacagatg 39acacat tattcaata acattgat atagctt cactagtaa tctttaatt 39ccact
tatgttac ttactgtat taacctt tacagatg gaaactaa 39caagt aagcactag ccaagcaag ttccagact gttcgtgt
cctgaatgct 3924ctcc agagtaag ttccagaag aatcaaga tctcagaga gactcagg 393gctt ctgctctg
ttccaatga ctctgctt ttactact ctgaatct 3936caa tagtagaagg cccagctag aggagtgaaa tgcacagca
tgtatctgc 3942caa ctgctctc tagcctcag ttccctca gtaaaatag tctctgac 3948ctcc aaaatgaa gcaattgt

acgtatgtat aggcattgcca tttttttt 3954tttt ccttgattc tcaaaagggt ccatgactgc ataaaaggat taagatccag 396ctgag
gaccttagg atccctgcc agatcaggcc aactaagttt gggctagcca 3966tacc cacccatctt cataagtgtc cagttgctgt
ccatttgctt ggcagcctgg 3972tagc gcccgctagt ccacatggtt gcatgctctt ctgtgatgat ggctgtgctt 3978gggg
agaaaaaaaa aagaagaaga aaggtttcta acaactgctc aaaagctgca 3984gaca gtagacaggc aagagcagta agaggcatca
gctcctagt gggcagatgg 399tgact ccaaagaac ctctgggcaa gagaagacca cactactgaa aacaagctgt 3996agct
ctgaaagaac agtctgaga cccaagctac ctggcactgg tcctgcaca 4aggactc cacttgcaaca gtatgagtca agaacagaga
atggagaact gtagacctat 4caaagtg gtctcgata atcaacaaga cacaggagg gatggttcct gctcagcaat 4agccact
cctctgctc accagacacc ccaggggagc tgtttacct ttctggaga 4accaagt gggccctatg agtgttctg ctgtggcacc
tagcaggaag cttatgcctc 4cctttat ctgccctccg tccccacagg cctggcagaa cttggggttt tggcagaggt 4agccaaa gccaatccta
atgcgccaac caacacaagc acttacgcca aaggaagcag 4gctaacc atgaggggag gggagctccc acctgtcca gcttgcttta
gagaacaaac 4aagtggg gagtccacc taaaactcaa aggcataatg gtttgagga acaccaatgc 4ttagagt taacctttgt tatttaagcc
aagagtgaac acagaaacca aaagccaagc 4tgggaga attatctggg accaataagc taagagagga ggttctgaaa ctatattaa
4tcatttc ttatttgggg tgctagtaac acaggtatat tcagtttaat tgatagaact 4atatgta ttttatattc aataaaaagt tcaaaaactt
tttaaaaata aaaattgta 4ctttgaa gcaaagatac agagaggaat aaaaagggtt actgaaaggt gaccttgggg 4agggaaa
gactgggaac ccacacctt ctgcagagag tcaatgtgga gcatctggtt 4attttct tttgcttct ataccacagg ctgaaactcg gttcagttat
tttaggagg 4acaaagg tgcagcaaga acagagaaaa agtagtgact cacccgcaga gccatcgaat 4gagacaa aagcccgcg
acagtcacat ggagcaatat actactctg gaaaacaaag 4acaacaa agtgggctc gatcagtcac gagcagactg ttctgctgc
ttagcctgt 4aggctca gcggggacta tgaagactgg ggaatcctg gccccgcc tcaagaagcc 4agtctag ctgaaaacaa
cagattgca cacactgcag aagattgaat taattaaggg 4agagagc tgttccctt agcctctatt tctcattag gagaacaaa
gcacatcagg 4aacagat aaaaactgct ctttctcac tgagatctta ctcaaaaate aaaccaataa 4ccttctc cctccttg

cactgacatt taggcatctg ttattttct gaaaagtaag 4gaatttc tgtgtaagc accaacaatt ccctaacta agtttctgta gatactgact
4ttccaaa ctctctgtt ggtctctct ctgaggtagc atccaate tctccatgc 4ccctgct cctctctgct acagagtgag cggaaacgct
tcatecaate caggagcctt 4caaaaata aatgtcatg tcaaaaacca aggtctctc agctgataat cctctgctt 4tatggaa ggggttaggg
agtgaagaaa gtaagaaatt ctacgcgtg ggcaaagggt 4agtcaaa gtgtgcaact tctgtaata gccagtgagg cacagagat
ttaagtaact 4cccaaat cacacagcta attaagtagc agaggcagga tttgaaccta agcagtcac 4agagtct ggactctgaa
gccctatgcc aggtgcca tgcatgacac ttatctctc 4ctcatca ctcttagga taagaccaat agcaaatgag aaaactgagg
ttcaagaga 4cttttaa gtaagctgcc cacttacaag ttaatagtag gtcaggatcc aaagccaggc 42ctgagt acagagctgc tgctcctct
gcagttacca ggattctcc aagccaaagg 42ggcaag gtaagaaag tttaggggtg ggaatggggc tgctggccag acccaaggca
42taggac agtcaacatg atgtaggggg aaaaggcct catgttctt tctgctata 42taagaa ctaccttt cagccaggca
cagtggtca tgcctgtaat ctagcactt 4224gctg aggtgggagg actgctgag cccaggaact cgagaccagc ctgggagcat
423aacct catgtctaca aaaaatacaa taattagcca ggcattggtg cacgtgctg 4236cagc tatttaggag gctgaggtg
gaggataatc tgagcccggg aggttaggc 4242gtga ggcattgatt tgccactgta ttccagccta ggcaacagag tgagacctg
4248aaaa ttaaaacaaa aattaacaaa aaaaaaaaa aggactgctt ctttaccac 4254ggca atcacagcct caaacagcc
tccagggaga tactagaagg gccagcatag 426caca tggcaggata aagcagctct gggccactg cccactagcc caggcccagc
4266gtct gcaacaagc ctggcagctc tctcagcctc atttctcat cttaagaca 4272ttca gattgctaaa tgcaacagca agcagcttt
attctaaag cataaagaac 4278tcaa cagcactaag gaaatagaaa gaaatggcca ccagatcgt tttagaactg 4284cctc
actgtttat taaccgagta attactgtg gcaagacttt ttataaaaa 429aacgg ggggaagggt ggccccacac tctctagga ctctgtgag
aaacagtaag 4296tctt tcaaaactca ccagaaactt gaaagtgtg cacatagca atggaagaga 43attaat ctctctcc taaacagta
gaagacatct aaggggctg gaaaactaag 43aaataa ctctgtgct aaaaactact ggcacaatg gggaatacac agtgagggca
43ccacca acatgagcc acaggctgg gctcttcca cccgtgacac agggtaaga 432gcaa gactggcaga gaatgcagtg
caggtctgag cccggctgga ctctccatt 4326cata gtactctagg gatccccac cctttctgg gcaagcttg gagagatgga
4332gcag gtttaccta gacttctca tcagcaaagg caaggaaaga gttctcca 4338gtgg aattaacagc aatggacat
gtttagttg gcatggagac aaggtctggg 4344atgt ccagacatga ctaagtgtt caacattca gaaagacatt gtaagcaag

435ccaca gcctcacctc cacactgaca ggctatgcag aagccagaca agcactgggc 4356ctgt cactctcctt ctcccaggca
tgaagctggc aacgccagg ggcggtctcc 4362caca gcatagggcc taaaataaac caaagctgta gcatgctagg aaaaaggcac
4368gcac agctgctggc ttttctcaa aaccaccac ttctctccat ttctaagc 4374cagt ccaagcctcc atcatcteta cctggactac
cgcccctaca atccactctg 438acact cagagtgage tttccaaat atctaagatc atgttagcaa cctccttaa 4386caat ggcttctat
tatatttaag ataaaatcca aactctggcc cagtcaaggt 4392tgat gtgactttgc cagtctctt gcagctctgc tcccattcac catgtccag
4398ccac ctctttttg ctctttgcat atcctaagct caatctgccc tcaaggcctt 44catgtg ctccatgtg cctataaaag tatttctgat
catggttaagg ttaggctctt 44tcatta cattgtgaga tcaaatatca cctctacaga gaggcctacc tgtactacc 44ataata gccacctggc
cacttttaag tctctgtata gcacacacat actctagata 4422tttt tttttttt tttctttgg agacaggatc gcctctgtt accctagcta
4428ggtg acacaattat ggctcattgt atccttgacc tctcaggtc aagcaatcct 4434caa tcttctcaat agctgggact acagcaggca
cacacctttt tttttttt 444tagaa acgggggttt accacgttgc caggctggcc tgaacttct gggctcaagt 4446cctg cctcagcctc
ccaaagtgtc aggattacag gcaagagcca ccatgctggg 4452ttct ctcttaatg aacttttat atgtttattg gcttgttct caacccccat
4458ccca agcatataag ttccatgaga tcagggtatc tctctgtccc ctgcactcag 4464tgac tagatcctca acccacattt gtattataa
tgaacaagca gaaagagaca 447ctttt cctacatcc agttaaace tcaaccatata ctacgaagat ggacgaagg 4476agcc
aaggaatgca ggtggcctcc agaaactgga aaaggcaagg aatggactc 4482gagc ctgcagaagt aacatagccc tctgacca
ttttagactt cagactcca 4488taag agaataaatt tgttttaagt cactgtggtata attgttata gcagtgatag 4494aata cattatctaa
tggggaaaag atcgttaaggg attataaatg gggtttcaa 45aatacc tcagggtaca ggacaaagga tatctttct aaagacagca
gctcctactc 45ctgatt tctgaaatgc agccacatg ttgctaacct tcaatattc agaagaagcc 45atattg gtctatgaga aattaccaa
tttttaatg ttggcatctata attccaaca 45aacaat acatagccaa ataaagcacc tgtaaactac aaaaaaaaaa aaagctagtc 4524caa
aatctggctc aagtgtccc tttccatga agcttctga ccaactcag 453agagg ctcccacatt tctgaattt acaggaccat ccatgttggc
acttatccat 4536cctt ggataatgt gacaaataat gtagctaaag attatttagt ctgtattgt 4542gtc tcaacaccta ctagtcaata
actgtattca tttctctca ttctaactc 4548agcc ctggaaggta tcatcctcg ctaactaca gatgaaaaa atgaagctta 4554taac
taactcccc aaggtaacac cacagtaaat ggcagaacca agatctgaac 456tctga cttttttt ttttaagatg ggtcttctt ttgtgctg
ggctggagt 4566cgca atctaggctc actacaacct ccactcca ggttcacgag attctcatgc 4572ctcc caagtagctg
ggattacagg cgcccaccac cacaccagc taattttggt 4578agta gagacagggt ttgcatgt ttgtcaggct ggtctcgaac
tctgacctc 4584tccg cctgcctega cctccaaag tctgaggat atggacatga gccactgcac 459ctcag gtctgactt
cgaaagccca tacccttga agctgccaag caactcttc 4596tga cagaagttgt acacatctag tctcacaatt ggattataa
ttctgagga 46ggaata cgaggtgtat gtgcactta cctctactt catcagccac agaatagaca 46ctaca ccagcagta gaactctgtt
caagcctggt tcccactta ctagtgggt 46ctgggg ctcaactcc tcatctgtaa aatggggatg aacataatgc ccacttgaa 462gaggt
gtgacataaa gcaattagc catgccgaac atctgatgaa ctgcagcact 4626tatg aactgcaccg agcttgactc tatagcaaac
ataagaaact atcttctga 4632caat cggcaatagt agacagatat tcatgaaat ataaacta ataaacagcc 4638acga tctgaaat
gcagtgtggt atttctata gtttaaagga tctcagatg 4644agat ccatcagacc aagctcagag gtttactgg gccaccaagg
ataggcgaag 465aggaa aacagtccag agggaaagggt gtgacaaggc ccagaagcaa gaggcaagag 4656catg aggcgacacc
caattagcct aatggcaggg gcaagaagtt caaggagca 4662gaga ttctgtaa ggccgtctga agacaaatag tcaaagacct
caaacaccag 4668aggc ttgaactta tctgcaagt tctagagaga cactaaaagt tgaagagagg 4674acat gaccagagct
gggttttaag aagaggatc aacatggctg gtcacatgcc 468aactt gccaaagtaa gctgacagct gactgccaag ataagcatga
ctaaagtac 4686ccac attagctga catctttccc ctccctgac cctctctcc catcagccat 4692ggca ctgtgctca aatatacaag
gttctcaaga aattgaaac tgaatgaata 4698catc ggtccacagg aagtacaaa agttagactg tgaatggaga tctggactcc
47ttcaa atataagta ttggcattt ttctctct aatgaaacc aagtcagggt 47gggaaa aactgacagt tgccaaaga tttgtctcc
ttccttagtg tagaagatc 47gaaagt agctgcccag ccaggcctc atcccatgc ctacattacat tgaggtgagg 4722gact tattctacc
aatgaaatgt gggtagagag tgatacctgg gtcggggctc 4728atga gtgtgcccgt tccactct gtcctctcc accagctaaa
atggtgttac 4734atgg aagagcctag atccctgaat cactttccct caaggtagag ggaagtcccc 474accag gaacaccac
tctactgct tacatgaaat aagaataag gctttacaat 4746ccac tgaactctg agatgtgta ccacagctag cattatteta acacaacaga
4752cact gtgggataaa aatcattaac cccacccca gagaaagcct gtttatgaa 4758acaa aacaggaagc tgaactcagg

agaatggagt aggggtccaaa gagtttagga 4764gaat catgtcttcc aggaggagga accacaaa aagccaaaaa ttcacattgg
 4777cagt cctgacaaa acatcacct ttgactaagc caagcccaac aacataat 4776tacg gatgaggagg atgaggaatc
 aagatttcta aaaggcagtg ctggcacagc 4782tcca accaaggatt ctctgcttt gaggcaagtg gtgcccacga atcccaat
 4788agga tggtagatga aagtatccag attaccagag agaacagagc attccttct 4794gtcc ccaggggccc aagctcatta
 atacaacaac cctaatacca caacccttgc 48agttta aaaagaagaa acccttagag ttgcagagga cagagagaag cagaccactg
 48gccaag tccttgcgta attatgcatt tgaggtacgt tttctctct gcagggaa 48gtgggt gtgtatatt gtgttttga aagtacaaa
 aggacagaat tcaagattcc 48cacttc tccaacaccc tcccctccc agccgttagga gaaactccat caaccagaa 4824ctga
 aatgaaaca ttaggaaaca gagccacagg gaacagcagc ctctctatta 483gagge tactatggca ggtcacacat gaagccagcc
 ctctctctt gttctcaaa 4836caag gatccagagt cccactaac agagtcgccc caactatgtg gctctctcc 4842acta aaacaaggaa
 cccatttct tctgttgatg gcaccacaaa cactcccagg 4848acct tccaatccc ctctaccacc tgctgcaag gtccacatt
 aatccaggtt 4854cttc tccaatcct accctctc tccgctccta acccagtag ccaagtccag 486cttta ccccaactct gagatcctgc
 aaggcctaac aggtttctca attccagag 4866ttct ccaaccata ctaaacactg ctccctctga tcatgtcact ctaaaatcct 4872ggtg
 gtcaaggaca accatgacca gtcaggggta attcatggat ggtcttaacc 4878ctgt tctccctct tcaagcttat tgcacat gttctctaa
 ttccatagat 4884ggta ttcttacca ttgatccag ccatctatt actgggtata taccacaaagg 489aaatc atgtgctat aaagacacat
 gcacacat gtttattgag gactattca 4896caaa gacttggaa caaccacat gtcacatgat gatagactgg atccagaaaa
 49gcacat atacacatg gaattctatg cagccataaa aaaggatgag tttatgtct 49agggac atggatgaag ctggaaacca
 tcattctgag caaactatg caaggacaga 49caaaaca ccgatgttc tcaactacag gtggcaactg acaatggaa catcacacac
 492cctgt catgggggtg ggggaggggg gagggatagc attaggagat atacctaag 4926atga gtaatgggt gcagcacacc
 aacatggcac atgtatacat atgtaaaaa 4932acgt tgtgctcatg taccctagaa cttaaagtat aatttaaaaa aagatttcca 4938ttct
 tgtactctc tccctcttc catgcatca aattctact gttcagttc 4944aaat cctactttct ccatgaagac tccctgac ctgccagct
 aaaactct 495ctttg aattcagttc acactttaag taaacttaca ttacagttgc caccagccac 4956ctaa gacttgaaa tgtggctatt
 gtgactgaga aacagaatac ttaattttat 4962ttaa taaattgaaa tacaattta aaaactgata tcaagattc agttactgga 4968ctaa
 gtatgtttag aacaactgg gtactgagtt ccacttttc aactgtcag 4974aaat ctaaacacag atcaaatatt tccaatgaaa atttcacatt
 caaattgcga 498tgtaa atgtaaaaa tcccatatt tgaaccaca gcataaaaag gaatgtaaag 4986ctta ataatttta taatgatgat
 gtgctaaaat aatattttg atatgttga 4992tatt gttaaaatta atttactgc tctttactt taatgtgtct atgagaacat 4998ttac
 atgtgtatct cacagattct acttagacag tgctaatgag gtccttccc 5acattca ccagtttct tttgtgtct catttatgac tgtggcttac
 ctattttta 5cttcaa agggatctc attcatctc acaacagtaa taacaacat agcggcagct 5atgacga gactttcaa gtgacatcaa
 gcattcaagc agcaagcatt caagtcttc 5cattcac atctacagta tgaaccatt tcatcctaac aatagcccat gcggtacata 5cactgc
 acaatctct tttgcgaat gcagaaactg agaccagaa agtttaattg 5cttcaga atttcatgta acttgctga tgcagcaaa ctagtaagta
 gcaaatctgg 5ctgaacc cagagaggt ctgagctca tacgcttacc tatatgctaa ctacctgccc 5gcatttg cccagacct
 agcctgagc agcagtcaga aaacatgcaa acaacaaaaa 5aatttct ccagtatgt aagacagaca gctaaactac agcaatagaa
 atgacagtta 5ttataaa agaaagagt gagaggggtg atgaagatgg aaggacagca agagtcaaa 5gtaagtc tgtgaagtct
 aaacagtac tctgcaata agagcaacag ctaacacaa 5agcttga tacattttgt atttccagga tttgctaca aaacacatct gtctcagatt
 5gcctcag tttctcatg gagggaaaag ccatctaat ctgatattgc aggatcatta 5ggagata aagagctgag ggaaagcctg
 gaacatccc tgtggcttag atggctcacc 5cactccc agaaggaatt gcttgggtg taataggcca cacctactgt caaagataga 5ttttaa
 gtatcagta ggggttcaa aatcagctt tatgatgacc aaacaaaca 5aagctgg caaaggaaca gcaccagga ccaagaacat
 caagataaac ttgactcagc 5aagatgt cgggtctcc tactagtaaa cacacagata atactaac tccaggcaaa 5aaactga aattgaata
 caaacactac aaagcttcca acacacctt aaccagaaac 5caactct taattcaagt aacattagca ggtcgaatct tctgtacac
 tgaggcctcc 5ggaggtg aagattcaca aatagtagag ctattaggag tctcagctg aggtccatg 5acctgtg agaaccctt
 cggaggaggg cccaatttc agacaactgt gccaggggac 5cagaact gcccaacca actgctacat aatcatcatg tctccagtt
 gcgggaacca 5ctgtctc aactaaca ggggtactgc aatcaaatca gcttaggca actgtccaat 5gtaaggg cagaaaata
 aaaatgccac tggatgattc agcagagaat ccaggtgaca 5agcccac atccaaaggc tgaggcctag gactgacagg aaacaaggaa
 gagctcatca 5gggccc aagaaaagaa aaacaaaat tcttgaaga caaggcaatg gtctgccc 5aatggg ggagtgccca

gctcctctgc tacctacgac tcataccata actcaggctc 5tcacagt ggccagccta ctctcacc cagtccttgg tcaagatgat attttgcttc
 5tgaagt ggtaacttt tttttttt ttttgagac agggctctgc tctgttgcct 5ctggagt gcagtggcgc aatctcagct cactgcaacc
 tccacctct gggttcaagc 5tctccca ccacagctc ccaagtactc aggactacag ccatgagcca ccacgcccag 5attttg ttttttg
 cagagatggg gtttccatg ttgaccagcc tggttcgaa 52tgacct caggtgatcc acctgectca accttccaaa atgctcggat
 tacaggcgtg 52accaca ccagcctga agttgaccaa tcttattgt ctatttaaat gaacacaaac 52ctcacc aagtctatcc ttaccttccc
 actgcctact agatctaaca gttatgcacc 522tcatg gcttctcacc atgccaccac cccgatcca gcttgatatt ctactttcc 5226ctgc
 caggctgaac agccagtgag ctgggtgcctg aatacacctc tcactctgac 5232cttc atccacctct acatgcaaga cccatcagc
 gatgaaaagt actatcacag 5238atat aaaggtatc catgaaacac tagagtctcc cacccegcc ctgaaataac 5244aatt
 ccatggacat ttaagtctga aaaatgctga atactttatc cctccttag 525cagag tgcacatcag catattaaag gcctgagaa
 gtctctcagc tatgaaactc 5256gcaa aggacttgaa tagacatttt ctcaaagaa aatatacaaa tgggacaaa 5262atga
 aaagatactc aacatcacta accatcaggt aatgcaaatc aatctacaa 5268atca cctcacaaca aaacaaaaaa tagcaagtgt
 tggtaggaa gtggaagaac 5274gctg tgtaccattg gtgggaatgc aaaatagtac aggtgctgca gaaaacagta 528gttcc
 cccaaaaatt aaaaatagaa ggatcatatg atctggcaat ctactttg 5286tacc caaagaatg gaaaacagga tctcaaaaag
 atacttgcaa acctatgtc 5292acat tactcacaat agccaagagg tggaaaaaac tgaatgacc atccacagat 5298gtta
 aaaaaaaaaa gtctctaaat aaaatggaat attattcagc ctataaaag 53aaatcc tgctatgt tacaacatgg atgaacctg gacactatac
 taagtgaat 53cagtca caaaaagaca aatactgcat gattccaatt acatgctta tctaaagcag 53actttt tttttgaga cggaatctcg
 ctctgtcacc caggctggag tacagtctg 5322cggc cggctcactg taacctccgc ctctcaggat caagcaaat ctctgcttc
 5328ctga gcagagggat tacaggcacg tctaccaag cctggctaat tttatattt 5334gaga tggggttca ccatgttggc caggctggc
 tccaactct gacctatga 534ctgcc tggcctccc aaagtctgg gattacagc gtagaccacc gtgactggcc 5346aatc
 ttagagagag aaagtagaat ggtggtgcc agggatagga ggggaggaga 5352ggga ggagctgtt aatggatata aagttcagt
 tttgcaagac gaaaaagttc 5358tctg ttgcacaaca atatgtcat gtagttaaca ctacagtatt gtacatttt 5364ttaa aataaatgc
 atattataca ttttcacca caataaaaaa aactgttca 537ttca ctatttctc aactaacaata tatattttt gtagagcacc ttacaagaca
 5376gaat actgaagaac acacacagtt tggggaacac tgttctaac atcaagat 5382cttc atactgttgc ctcaaatatc cgtacctt
 gcttattcat ttcaagcct 5388gctc ctaaggccag gaaatccatg tctccaggca gagatccaat cttgaggtt 5394tccc aggttaatac
 aggcctgacc ttgtcgcaac catgtagacc aggacctctg 54gaggca ggaagtcagc cagccagaat ggacatgtt tgtgatctt
 gctcaactta 54aatacc cttatctacc acccctcca tcatggtgga ctggtggacc cccattactc 54ctgaca tcacacagac
 acacacacag acacagacac gcacacgtgc acacacacag 54accagg acctgcaga accaagttgc tacatatacc aatcaagttc
 tcatctgga 5424attt gggggattaa ggttctagtt caatctgga tcttgaaagt aagagaggaa 543ataaa tgtaggtgtt gtcaggtta
 tatgaccaa ccagttggct gaaaaagaga 5436tatg cagcaagacc tgaaaacct cccgtcccag ttcttctga gggcctgcta
 5442tgcc ctcatgttcc acaagacacc ctatctgagg cctgacaca cataactctg 5448ccat tcacaatctg gagtgtgccc
 aatatggtgg ctctgcccctt gaatectat 5454tttt tattgtcaa ggtatctcaa ggcagttct attactgca actgaagaat 546aacia
 cagctttatt tcccact gcttttact tccctgtct cttgccagg 5466gtcc cactgttct gaagagcacc cgaagctcc ctgtttctt
 gccttctg 5472atac tttacctag aacctctc ctctctcc acccctccc tctattacc 5478ccac ccactctca aggtccaat
 caactgtct cctgtgcca tgaagctctt 5484cttc cctctcacc ctcaactc cacagcttc tctcagatt ttctgatca 549accac
 atttacctt acaatacagg tatgtgcatg tacatctaaa ctccattatt 5496tatg ctcttaaaa ccaggaacaa tctctctc tatatcatg
 ctaatacctg 55gggtag ggccttatac ataagtaaag gctgggaaaa actgtactta tagatgattc 55gaagaa tagcactctt atattttc
 atctctact aaaccataag ctagtgaga 55acattc aaccttaagt tcatcttgc acctacagc accataacca cagtgaagc 552aacac
 ttgctgactc aatgactca cagtggatcc tagaatcctt ttacctacc 5526caac cctatcacat gaggtctctg cctctccaac tctctggat
 tgggcaaaaag 5532aggc caaacaattc tcttagaac acagtgtggc agaggagatg tggagtatgc 5538caga aagttccaga
 acttctgccc ctaatttgc ccaataatc ttattgaaa 5544taag tcaactggaat caaggaagct agggccaatc cacaagcatt
 cagtgagacc 555gacac agatcccat agcaagcct ggaagggctt ggtgtggccc ctggttggg 5556aatt agaactctac
 aaacacatta gggctgggga aaaaagactg aaaagaaagg 5562ccat tgccatgcag tactgatga gcactcccg atgggatgat
 gtaggcctgg 5568ctgg tcacatactc agagtctc atggttctc tcaagctccg aagcagctct 5574acct ttggaggcat tctgcccct

gcaacaacag gagagcaaat tcaaaaacca 558cccc agcaattcaa cgtccagttc gaagtgggcc acagagagaa gtccttcta
 5586gccc cactccagtaggtcttca aattgatcac tccaccacca gaccaagacc 5592gcca gaaacactaa tgttcacagt
 tettaaatac tactccaaa tagccattg 5598gaaa agttcagcta ctaaccattt ccaacttgac tggttaccte tttcactcct 56ctttat
 tcaagaatag gagataagta cacagaaatt taggtgttta tctttgttta 56agaaaa aagcaggaga agtgtatggt cagttaaata aactataata
 cgtacaacag 56ctgtgt actcattaa aattacacag acctagaaaa gaattacata gacttatata 5622ttgg aaagatacct agacaacatt
 tgtgggtgat taaaaacaga tgacaggctg 5628gtgg ctacgcctt taattccagc actttgggag gccaaagcag gcagatcaca
 5634ggag atcgagacca tctggccaa tatggtgaaa cccctctct acaaaatata 564tcagc caggtgtggt

ggcacgtgcc tgtagtccca gctactccgg aggetgagc 5646atca cttgcactca ggaggtggag gttgcagtga cctgagacca
 caccactgca 5652cctg gcaaaagacc aagactccgt ctcaaaaaac aaaacaaaac aaacagatga 5658aaaa aatatagat
 tgttcttatt tatttaaat tgtgtatgta tatatgcaa 5664tttc tagaaggaca gtcaccaag tgtaagagt ggttacctt gggtagtaa
 567gagta attattgtct tctgtattt ttctgcttt taaattgac tgcttataaa 5676gttt tataaacctt ttgttaaata tccagctaca
 gattagaga agaaagttcc 5682tagg agtcaaaagt cttatcttct agtgaatacc tgctaccaac cagctgtgca 5688aagg
 ggaccaggcc ctcaatgctc tgtgttctcc tctttaaagt atggcgggag 5694ggtg cgggtgctca cactgtaat cccagcactt
 tgggaggcca aagcaggcgg 57caaggt caggagatcg agaccatct ggctaacatg gtgaagcccc gtctacta 57tacaaa
 aaagttagcc agcgtggtg gcgggtgctt gtagccag ctactcagga 57gaggca ggagaatggc gtgaaccgg gaggcagagc
 ttgcagtgag ccaggattgc 57ctacac tccagcctgg gcaacagagt gagactctgt ctcaaaaaaa taaataaata 5724ggcg
 ggagtggatg agaccaagg tttcaaacg aagtcccaag gctccagggg 573acat tcaataaaaa ccagagttgg aatcaccagc
 ttagaaaat acaaaatagg 5736aata taaaactaat taaaatgaaa tgtaagat gtaactctg gtctactag 5742ttaa acttgttca
 tctatatcta tagtcaggaa tagtctctg tactcactta 5748gcac agatgataca agctgactta accactttag ttggttctc aaaaagacct
 5754aaca atcactgata ttagttaatg ttctgataaa catcatagct gtagtctat 576cataa caaacaact tcagaaggag ccaattacag
 aatagtgate atgcatatt 5766atcc catatactgg cacaaaacta tactattaga attcaaagta gaataatgag 5772caac tcattttaa
 tagacttcat ttttacagc agttatagtt tcacagcaaa 5778caga aaatacagag tccccatga gctccagccc caacacacac
 acagccccct 5784atct gcatcccaaa ccagagtagt acatttgta aatggatta acttacatta 579tcate atcaccctag gtccacagct
 tactctgca ttatctgtg gtgtgtaca 5796gggt tttgaaaaat gtgtaatggc atgtatccac cattatagta tcacacagag 58ttcact
 gccctgaaaa ttctatatgc acatgcagcc tattcattcc tcttctctc 58ctctaa cccgacaata actgagcttt tctactgtct ccatagttt
 gcctgttcta 58gtcata cagttagaaa cattctacac agagctttg ccagattgat ttctgtctac 582gaata atgcatttaa gccaggcgca
 gtggctcaca cctgtgtgcc cagcgttaag 5826gcta gtggatcacc tgaggttggg agctcaagac cagcctgacc aacatagaga
 5832atct ctactaaaaa taaaaatta gctgggcatg gtggcacatg tctgtaatcc 5838ctca ggaggtgag gcaggagaat
 tgctcgaaca caggaagcag aggtgtgtgt 5844agat cacaccattg cactccagcc tgggcaaaa aagcgaaact ctgtctcaa
 585aaaaa aaagacaata tgcatttaag gttctctat gtctttgat tgctgatag 5856tttt tagccctgaa taatactcca ttgtctgag
 gtaccacat ttatcattc 5862tgag ggacatattg gttgttcca ggttctgta atcatgaata aagctgctat 5868ctgt gtgcagttt
 tagtgagc taagattcca actcattgg tttt 58735

* * * * *

8.

[\[View Shopping Cart\]](#) [\[Add to Shopping Cart\]](#)

[Top](#)

[Home](#)

[Quick](#)

[\[Manual Search\]](#)

[Pat Num](#)

[\[Help\]](#)

<A Name=hb HREF=#h<A Name=h2 HREF=#h<A HREF=/netacgi/nph-Parser?SectSect2=HITOFF&p=netahtml%2FPTO%2Fsearch-bool.html&r==5ND&d=PTXT&s